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Abstract
Cells constantly encounter changing environments that challenge the ability to adapt
and survive. Signal transduction networks enable cells to appropriately sense and respond
to these changes, and are often mediated through the activity of protein kinases. Protein
kinases are a class of enzyme responsible for regulating a broad spectrum of cellular
functions by transferring phosphate groups from ATP to substrate proteins, thereby
altering substrate activity and function. PERK is a resident kinase of the endoplasmic
reticulum, and is responsible for sensing perturbations in the protein folding capacity of
the ER. When the influx of unfolded, nascent proteins exceeds the folding capacity of the
ER, PERK initiates a cascade of signaling events that enable cell adaptation and ER
stress resolution. These signaling pathways are not only essential for the survival of
normal cells undergoing ER stress, but are also co-opted by tumor cells in order to
survive the oxygen and nutrient-restricted conditions of the tumor microenvironment. Not
surprisingly, PERK signaling is known to influence a variety of pro-tumorigenic
processes. Therefore, from a purely biological standpoint as well as from a clinical
perspective, it is important to understand this critical cell adaptive pathway in greater
detail through identifying its interacting partners and thereby elucidating additional
downstream signaling branches.
Prior to the work described herein, only three direct PERK substrates had been
identified. Using chemical-genetic screening techniques, we have generated a significant
list of putative PERK substrates, several of which have been confirmed as PERK
substrates in vitro. These preliminary results suggest new connections between known
UPR pathways, as well as entirely novel signaling branches downstream of PERK. This
work will provide a solid foundation for launching future PERK-related discovery
studies.
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ABSTRACT 
A CHEMICAL-GENETIC SCREEN FOR IDENTIFYING SUBSTRATES  
OF THE ER KINASE PERK 
Nancy L. Maas 
J. Alan Diehl 
 
     Cells constantly encounter changing environments that challenge the ability to adapt 
and survive. Signal transduction networks enable cells to appropriately sense and respond 
to these changes, and are often mediated through the activity of protein kinases. Protein 
kinases are a class of enzyme responsible for regulating a broad spectrum of cellular 
functions by transferring phosphate groups from ATP to substrate proteins, thereby 
altering substrate activity and function. PERK is a resident kinase of the endoplasmic 
reticulum, and is responsible for sensing perturbations in the protein folding capacity of 
the ER. When the influx of unfolded, nascent proteins exceeds the folding capacity of the 
ER, PERK initiates a cascade of signaling events that enable cell adaptation and ER 
stress resolution. These signaling pathways are not only essential for the survival of 
normal cells undergoing ER stress, but are also co-opted by tumor cells in order to 
survive the oxygen and nutrient-restricted conditions of the tumor microenvironment. Not 
surprisingly, PERK signaling is known to influence a variety of pro-tumorigenic 
processes. Therefore, from a purely biological standpoint as well as from a clinical 
perspective, it is important to understand this critical cell adaptive pathway in greater 
detail through identifying its interacting partners and thereby elucidating additional 
downstream signaling branches. 
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     Prior to the work described herein, only three direct PERK substrates had been 
identified. Using chemical-genetic screening techniques, we have generated a significant 
list of putative PERK substrates, several of which have been confirmed as PERK 
substrates in vitro. These preliminary results suggest new connections between known 
UPR pathways, as well as entirely novel signaling branches downstream of PERK. This 
work will provide a solid foundation for launching future PERK-related discovery 
studies. 
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CHAPTER ONE 
                                                   INTRODUCTION 
 
1.1 The Unfolded Protein Response  
The endoplasmic reticulum (ER) is a highly specialized organelle that governs the 
synthesis, folding, and maturation of approximately 30% or more of total cellular protein 
(Shimizu & Hendershot, 2007). It is composed of multiple layers of stacked cisternae, 
within which proteins are co-translationally folded and modified by N-linked 
glycosylation and disulphide bonds. The ER is far from a simple, passive folding 
environment, however. It is in fact highly dynamic, equipped with signal transduction 
networks that closely monitor protein folding efficiency and respond to environmental 
changes that challenge ER homeostasis. When the influx of unfolded, nascent proteins 
exceeds the folding capacity of the ER, this imbalance is sensed by ER stress sensors that 
initiate a cascade of events aimed at restoring homeostasis. This adaptive response is 
termed the Unfolded Protein Response (UPR). Limitation of nutrients and oxygen have a 
direct impact on the efficiency of protein folding in the ER, and are classical inducers of 
this signaling pathway. Not only does the UPR regulate ER homeostasis in normal cells 
experiencing such stress, but strong evidence also suggests that tumor cells can co-opt the 
cytoprotective aspects of this response in order to survive the hypoxic, nutrient-restricted 
conditions of the tumor microenvironment.                                                                                           
1.1.1 Signal transduction in response to ER stress 
The UPR is mediated by three primary ER stress sensors: (PKR)-like ER kinase 
(PERK), inositol-requiring gene 1 (IRE1), and activating transcription factor 6 (ATF6), 
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all of which are embedded in the ER membrane (Figure 1.1). Under homeostatic 
conditions, the ER chaperone GRP78/BiP associates with the luminal domain of each of 
these these three effectors thereby inhibiting their activation (Bertolotti et al, 2000; Shen 
et al, 2002). Upon ER stress, accumulating unfolded proteins require increased chaperone 
activity resulting in GRP78/BiP titration. PERK and IRE1 are thus released, triggering 
their activation by permitting oligomerization and trans-autophosphorylation (Bertolotti 
et al, 2000). Release of GRP78/BiP from ATF6 exposes an ATF6 Golgi localization 
signal, leading to its translocation and activation by proteolytic cleavage (Shen et al, 
2002). 
     Current evidence supports a model wherein the immediate effects of UPR activation 
are cytoprotective and PERK is pivotal for cell adaptation to ER stress.  PERK 
phosphorylates the eukaryotic translation initiation factor eIF2α, which inhibits general 
protein synthesis and lowers the protein load (Harding et al, 1999; Shi et al, 1998). Also 
important for ER stress resolution is the PERK-dependent downregulation of cyclin D1 
through eIF2α. Inhibition of cyclin D1 synthesis triggers a G1 cell cycle arrest, thereby 
reducing cellular biosynthetic needs and providing a window during which to re-establish 
ER homeostasis (Brewer et al, 1999). In addition to limiting protein influx through 
eIF2α, PERK directly phosphorylates the transcription factor Nrf2, which contributes to 
cell survival through maintaining redox homeostasis. In unstressed cells, Nrf2 is held in 
an inactive state through binding the cytoskeletal anchor protein Keap1. With ER stress, 
PERK phosphorylates Nrf2, triggering its release from Keap1. This facilitates 
translocation of Nrf2 to the nucleus, where to it regulates the expression of detoxifying 
enzymes and thereby protects cells from oxidative damage (Cullinan et al, 2003). 
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Through PERK, there is also a selective upregulation of certain factors, notably the bZIP 
transcription factor ATF4. ATF4 induces expression of pro-survival genes involved in 
protein folding, redox homeostasis, and amino acid metabolism (Harding et al, 2003; 
Hetz et al, 2013). Following prolonged or acute ER stress, ATF4 also targets the pro-
apoptotic transcription factor GADD153/CHOP (Tabas & Ron, 2011). CHOP expression 
leads to cell death, suggesting a unique role for PERK in cell fate determination. 
IRE1 provides important adaptive signals through activation of the X-box protein 1 
transcription factor (XBP-1). IRE1 endoribonuclease activity is responsible for 
processing XBP-1 via a splicing mechanism that shifts the reading frame to encode a 
stable, active transcription factor (XBP-1s) (Calfon et al, 2002; Lee et al, 2002; Yoshida 
et al, 2001). XBP-1 target genes include key factors involved in protein folding, ER-
associated degradation (ERAD), and ER expansion under stress (Acosta-Alvear et al, 
2007; Lee et al, 2003). IRE1 RNase activity also contributes to ER stress resolution 
through regulated IRE1-dependent decay (RIDD) of mRNA (Hollien & Weissman, 
2006). This pathway in conjunction with PERK-dependent translational repression may 
serve to reduce the influx of ER-bound proteins during ER stress. 
Contributing to the adaptive transcriptional program, ATF6 transduces signals from 
the endoplasmic reticulum to the nucleus via its cytosolic bZIP domain. Following 
proteolytic processing in the trans-Golgi, the cleaved form of ATF6, ATF6(N), is 
released to translocate to the nucleus where it targets ERAD components as well as XBP-
1 itself (Yamamoto et al, 2007; Yoshida et al, 2001).             
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1.1.2 Oncogenic UPR signaling 
Provided the cytoprotective effects of the UPR during stress, it is not surprising that 
cancer cells might co-opt the UPR for tumor perpetuation.  As tumor cells begin to 
proliferate and expand into surrounding tissue, there is an ever-increasing demand for 
nutrients and oxygen. This quickly exceeds the capacity of existing tissue vasculature to 
support such demand, creating an environment of glucose and oxygen restriction that 
challenges tumor expansion. These conditions impinge on the proper folding and 
maturation of secreted proteins in the ER, which is immediately sensed by the three ER 
stress sensors. The ensuing response enables tumor cell adaptation and survival.  
     Consistent with the idea that UPR signaling supports tumorigenesis, major UPR 
mediators are often upregulated in cancer and have been implicated in critical stages of 
cancer progression (Hetz et al, 2013; Ma & Hendershot, 2004). The overexpression of 
IRE1 and ATF6, as well as of the ER chaperones GRP78/BiP, GRP94, and GRP170 in a 
variety of cancer types offers a case in point (Fernandez et al, 2000; Shuda et al, 2003; 
Tsukamoto et al, 1998). Functionally, UPR signaling contributes to a broad spectrum of 
cancer-related processes including cell survival, migration, metastasis, autophagy, 
angiogenesis, and chemotherapeutic resistance. The importance of this response has been 
demonstrated through genetic and chemical-based manipulation of UPR components in 
tumor models in vivo. Recent work exploring the effect of XBP-1 and PERK deletion are 
prime examples of the requirement for ER stress signaling in tumor growth (Bi et al, 
2005; Bobrovnikova-Marjon et al, 2010; Romero-Ramirez et al, 2004). Paradoxically, 
both PERK and IRE1 have also been suggested to contribute to tumor suppression (Auf 
et al, 2010; Denoyelle et al, 2006; Donze et al, 1995; Perkins & Barber, 2004; 
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Ranganathan et al, 2008; Sequeira et al, 2007). These observations suggest that the 
contribution of UPR signaling to tumorigenesis is highly context-dependent, and 
underscores the need for more clearly defining UPR signaling branches and their 
underlying molecular mechanisms. 
 
1.2 PERK signaling in normal cells and in neoplastic progression 
     As one of the master regulators of the ER stress response and a key pro-survival 
effector, PERK has received considerable attention in the context of tumor 
initiation/progression. It has been characterized for its role in tumor growth, cell 
migration, metastasis, angiogenesis, survival of ECM-detached cells, and the epithelial-
mesenchymal transition (Avivar-Valderas et al, 2013; Avivar-Valderas et al, 2011; Bi et 
al, 2005; Blais et al, 2006; Bobrovnikova-Marjon et al, 2010; Feng et al, 2014; Mujcic et 
al, 2013; Nagelkerke et al, 2013) (Figure 1.2). In light of these pro-tumorigenic effects, 
there has been significant interest in developing cancer therapeutics that target PERK 
activity, and in defining the molecular mechanisms that underlie PERK function. These 
studies have not only begun to explore the multi-faceted nature of PERK in 
tumorigenesis, but have also highlighted the critical contribution of PERK to pancreatic 
beta cell fitness and survival. 
1.2.1 Normal PERK activity supports pancreatic function and skeletal development 
     Early studies first suggested a link between PERK and skeletal/pancreatic  
development through correlating PERK loss-of-function mutations with the incidence of 
Wolcott-Rallison syndrome (Delepine et al, 2000). This rare genetic disorder is 
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characterized by early-onset insulin-dependent diabetes, skeletal dysplasia, growth 
retardation, and hepatic dysfunction (Julier & Nicolino, 2010).   
     The requirement for PERK in pancreatic beta cell fitness and survival was later 
demonstrated through studies utilizing chemical PERK inhibitors (Atkins et al, 2013; 
Harding et al, 2012), and genetic mouse models in which PERK was either 
conventionally excised (Harding et al, 2001; Zhang et al, 2002), or excised postnatally 
(Gao et al, 2012). PERK excision resulted in apoptotic loss of insulin-secreting beta cells 
and acinar tissue (Gao et al, 2012; Zhang et al, 2002); beta cell loss was presumably 
triggered by an accumulation of misfolded proinsulin and mediated through activation of 
the remaining UPR branches (Gao et al, 2012). PERK-deficient mice experienced 
compromised glucose homeostasis that quickly led to hyperglycemia. These symptoms 
occurred regardless of age at PERK excision (Gao et al, 2012), suggesting that PERK 
function is not only required during early beta cell development but also for adult tissue 
homeostasis. Consistent with these reports, PERK inhibition via small molecule 
inhibitors also resulted in aberrant insulin maturation in Min6 beta cells as well as rat 
pancreatic islets (Harding et al, 2012), and led to degeneration of both islet and acinar 
cells accompanied by a 50% decrease in pancreas weight in mice (Atkins et al, 2013).  
     PERK is also required for normal neonatal skeletal development, as suggested by the 
multiple skeletal dysplasias exhibited in Rallison-Wolcott syndrome in humans, and the 
recapitulation of such symptoms in PERK-deficient mice (Julier & Nicolino, 2010; Wei 
et al, 2008; Zhang et al, 2002). Further investigation of the osteopenic phenotype in 
PERK-/- mice revealed poor differentiation and expansion of osteoblasts, and abnormal 
retention of procollagen I in the ER (Wei et al, 2008). Type I collagen is normally 
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secreted by mature osteoblasts, and is required for proper bone formation. Since PERK is 
required for appropriate ER-Golgi trafficking (Gupta et al, 2010), it is not surprising that 
lack of adequate PERK activity would result in failure to transport and secrete collagen, 
and that this would lead to severe osteopenia. 
1.2.2 PERK promotes tumor cell proliferation and survival 
     Deletion of PERK, ATF4, or Nrf2, or mutation of the PERK-mediated eIF2α 
phospho-site were demonstrated to have deleterious effects on cell survival following 
chronic ER stress in cell culture (Bi et al, 2005; Cullinan et al, 2003; Harding et al, 2000; 
Ye et al, 2010). Consistent with these observations, tumor growth was significantly 
impaired with PERK excision in ectopic and orthotopic tumor models (Bi et al, 2005; 
Bobrovnikova-Marjon et al, 2010). Furthermore, mammary gland-specific PERK 
knockout in the MMTV-Neu breast cancer model delayed tumor onset and reduced 
metastatic lesions. In this study, PERK knockdown triggered oxidative DNA damage and 
activated the DNA damage checkpoint in breast cancer cells and orthotopic tumors, 
suggesting a mechanism whereby tumor cell proliferation and survival are attentuated 
through PERK loss (Bobrovnikova-Marjon et al, 2010). Recent work has also 
demonstrated a significant pro-survival effect of PERK on ECM-detached mammary 
epithelial cells; PERK is activated upon cell detachment and induces autophagy via 
AMPK/mTORC1 regulation, thus protecting cells from anoikis (Avivar-Valderas et al, 
2013; Avivar-Valderas et al, 2011). Additional pathways through which PERK likely 
contributes to cell survival are the PI3K-Akt and NFkB networks, however, these 
mechanisms have not yet been fully elucidated.  
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1.2.3 PERK contributes to metastatic progression  
     Metastasis of primary tumor cells to a distant site requires multiple steps that 
challenge a cell’s ability to navigate harsh conditions. Cells must detach from the primary 
site, migrate through surrounding tissue, enter and survive blood stream circulation, and 
finally, extravasate to colonize a secondary site. Successful completion of these steps 
requires altered cell-cell and cell-substratum contacts and acquisition of a more 
migratory, invasive phenotype. While previous work suggested a PERK-dependent effect 
on metastasis, it is not until very recently that the details of its pro-metastatic influence 
are beginning to become clear. These lines of investigation have centered around 
regulation of a previously uncharacterized metastasis-associated gene, LAMP3. LAMP3 
is transcriptionally upregulated in several tumor types, as well as in response to hypoxic 
conditions in various cancer cell lines. This response is PERK-eIF2α-ATF4 dependent, 
though direct regulation by ATF4 has not yet been shown (Mujcic et al, 2009). 
Furthermore, depletion of PERK, ATF4, or LAMP3 inhibits migration in breast cancer 
cell lines (Nagelkerke et al, 2013), with subsequent studies demonstrating an inhibitory 
effect on invasion and metastasis in vivo (Mujcic et al, 2013).  
     A connection between PERK signaling and the epithelial-mesenchymal transition 
(EMT) has also been proposed (Feng et al, 2014). EMT is a transition from epithelial, 
cuboidal morphology with tight cell-cell junctions to a more motile, invasive, 
mesenchymal cell type. EMT contributes to normal development and to oncogenic 
transformation; in the latter context, it is thought to facilitate metastatic progression. 
Agents that induce ER stress can induce an EMT-like transition (Ulianich et al, 2008).  
Supporting these observations, recent work demonstrated specific activation of the 
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PERK-eIF2α-ATF4 branch of the UPR in cells undergoing EMT, as well as a positive 
correlation between ATF4 expression and EMT genes in primary human tumors. 
Moreover, PERK signaling was required for the migratory and invasive properties of 
these cells, as well as the metastatic capability of 4T1 cells in vivo (Feng et al, 2014). 
1.2.4 PERK promotes angiogenesis 
     Tumor expansion requires adequate tissue vasculature to support such growth. Tumor 
angiogenesis is the penetration of new blood vessels into cancerous tissue to provide 
tumor cells with nutrients and oxygen, and remove waste. Vascular endothelial growth 
factor (VEGF) is a secreted protein that was originally thought to be specific to 
endothelial cells (Leung et al, 1989), and has been shown to promote angiogenesis and 
vascular hyperpermeability. Interestingly, expression of the most abundant of this family, 
VEGFA, is induced 2-5 fold with ER stress in numerous cancer cell types (Ghosh et al, 
2010). This upregulation was mediated by all three branches of the UPR: IRE1, PERK, 
and ATF6 in a HIF1α-independent manner. Consistent with these observations, 
subsequent work using a tumor xenograft model demonstrated diminished vascular 
density and perfusion in mice treated with the PERK inhibitor GSK2656157 (Atkins et al, 
2013). Furthermore, VEGF activated PERK, IRE1, and ATF6 through PLCγ/mTORC1 
crosstalk in endothelial cells, and that signaling through PERK and ATF6 are required for 
endothelial cell survival (Karali et al, 2014). Collectively, these data suggest a potential 
positive feedback mechanism whereby VEGF secretion stimulates angiogenesis while 
activating UPR signaling; UPR activation promotes cell survival while feeding back to 
stimulate increased VEGF expression. 
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1.2.5 PERK signaling and tumor dormancy 
     Following chemotherapeutic treatment and regression of the primary tumor, patients  
can experience a period of remission followed by relapse due to metastatic disease that is 
apparent at the time of initial treatment. Some patients relapse following a relatively 
extended disease-free period, suggesting that tumor cells can also survive 
chemotherapeutic treatment to lie dormant in the body until later reactivation. Key 
properties of dormant tumor cells are G0-G1 cell cycle arrest and enhanced survival, both 
of which are also consequences of PERK activation. Consistent with the idea that PERK 
can therefore contribute to tumor dormancy, studies using human squamous carcinoma 
cell lines demonstrated increased resistance to doxorubicin-induced apoptosis in the 
dormant tumor cells (D-HE3p) when compared to those that were aggressively 
tumorigenic (T-HEp3) (Ranganathan et al, 2006). Increased drug-resistance was 
dependent upon PERK activity, which was in turn dependent upon p38. Although these 
studies were not conducted in vivo, the data suggest that PERK may play a role in 
promoting tumor dormancy which can protect the host during early stages of tumor 
progression, but may also endanger the host in later stages by protecting tumor cells until 
more favorable conditions arise.  
1.2.6 PERK as a tumor suppressor 
     Though the prevailing view of PERK is as an oncogenic effector, PERK has also been 
proposed to play a role in tumor suppression in certain contexts. This adds an additional 
layer of complexity to its study not only from a purely biological standpoint but also from 
a therapeutic perspective. Early studies demonstrated oncogenic transformation of NIH-
3T3 cells with inhibition of eIF2α phosphorylation (Donze et al, 1995), as well as 
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transformation of primary human kidney cells with expression of an eIF2α phospho-
mutant (Perkins & Barber, 2004). Moreover, expression of a dominant-negative PERK 
mutant in mammary epithelial cells resulted in hyper-proliferation, and orthotopic 
implantation of these cells promoted mammary tumor formation (Sequeira et al, 2007), 
while PERK activation inhibited tumor growth in a colon cancer model (Ranganathan et 
al, 2008). Collectively, these studies suggest a role for PERK in cancer is highly context-
dependent, underscoring the need for further definition of its mechanisms of action and 
downstream target activation under varying conditions, environments, and stages of 
cancer progression. 
 
1.3 Chemical-genetic approaches to exploring kinase function and pathway 
mapping 
     Protein kinases are important regulators of normal and tumor cell biology, PERK 
being a prime example.  Analysis of their functional properties in the context of disease is 
of vital importance. From a therapeutic standpoint, this is reflected in an intense focus on 
kinase inhibitor development, and in the array of kinase inhibitors currently in clinical 
trial (Fedorov et al, 2010). Despite the demand for kinome profiling and kinase 
characterization, this area of study has proven challenging. When employing the use of 
small molecule inhibitors to study kinase function, the fact that most inhibitors often 
target the conserved ATP-binding pocket presents a specificity issue. On the other hand, 
genetic manipulations (i.e. kinase deletion) achieve specificity in that only the kinase of 
interest is targeted. This method, however, has the drawback of depleting the kinase for 
an extended period, during which compensatory mechanisms and indirect downstream 
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effects are often confounding. This method also cannot distinguish between effects due to 
loss of kinase activity and those due to loss of the entire protein. Chemical-genetic 
techniques have recently enabled significant advances in this field. Using a system 
whereby the kinase of interest is genetically altered to selectively bind a bulky inhibitor 
analog has offered benefits of both transience and specificity.  
1.3.1 Analog-sensitive kinases to interrogate kinase function 
     The concept of an analog-sensitive kinase, i.e. a kinase that has been genetically 
engineered to bind a specific ATP analog, was first introduced through work from the 
Shokat lab (Bishop et al, 1998; Bishop et al, 2000). The tyrosine kinase v-Src was used in 
these studies, due in part to the inability of established Src inhibitors to distinguish 
between closely related family members, which hindered the study of individual Src 
function. A conserved site in the ATP binding pocket was identified (Ile 338) and 
mutated to a smaller amino acid, generating a “hole” that could serve as a specificity 
pocket (Figure 1.3). An ATP-competitive analog with a corresponding “bump” was then 
synthesized, such that the binding between analog and kinase was akin to a lock-and-key 
model. Importantly, alignment of v-Src with all other known eukaryotic protein kinases 
revealed a residue with a bulky side chain at the site corresponding to Ile 338. Wild type 
kinases lacking the engineered specificity pocket should therefore not be able to bind the 
bulky inhibitor. Highly specific inhibition of the mutant kinase by a panel of modified 
pyrazolo[3,4-d]pyrimidine (PP1) inhibitors was demonstrated both in vitro and in the 
context of intact cells; moreover, in a functional assay, inhibition of the v-Src 
transformed cell morphology was observed only in cells expressing the mutant kinase. 
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Thus, this approach provided a high degree of specificity that is not often achieved by 
small molecule inhibitors. 
     The conserved residue in the ATP-binding pocket whose mutation confers analog-
sensitivity has since been termed the “gatekeeper” residue, as it blocks access to a deeper 
hydrophobic pocket that can be accessed through space-generating mutation. It has been 
demonstrated through numerous subsequent studies that simple alignment of primary 
sequence can accurately predict the gatekeeper residue. This allows this strategy of 
kinase sensitization to be extended to identify analog-sensitive alleles of other kinase 
families. As testament to the appeal of this method, analog-sensitive alleles have been 
generated for at least 85 kinases to date (Zhang et al, 2013a). 
1.3.2 Analog-sensitive kinases for substrate identification/pathway mapping 
     Analog-sensitive kinases are not only used for studying kinase function, but have also 
been recently employed for network mapping, i.e. for identifying direct kinase substrates 
(Allen et al, 2005; Allen et al, 2007; Banko et al, 2011; Blethrow et al, 2008; Chi et al, 
2008; Ubersax et al, 2003). In the past, substrate identification has been approached 
through various genetic and chemical-based methods including genetic screening, protein 
and peptide array screens, in vitro lysate phosphorylation coupled with mass 
spectrometry, yeast two-hybrid screens, and bioinformatic analysis (Johnson & Hunter, 
2005). The only technique that can screen for direct interaction on a genome-wide scale, 
however, is use of an analog-sensitive kinase. 
     Wild type kinases transduce signals by transferring a phosphate group from ATP to 
serine, threonine, or tyrosine residues of substrate proteins. With a chemical-genetic 
approach to substrate identification, the analog-sensitive kinase uses N6-alkylated ATPγS 
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to transfer a thiophosphoryl rather than a phosphoryl group to its substrates. The bulky 
side chain confers specificity for the analog-sensitive kinase, and the thiophosphoryl 
group acts as a label for distinguishing direct substrates from all other phosphorylated 
proteins in the cell (Figure 1.4). The thiophosphoryl moiety can then be used as a 
“handle” for affinity purification of labeled substrates, followed by identification via 
mass spectrometry.  
     Traditional methods for PERK substrate identification have thus far revealed only 
three direct targets. Realizing that approximately one-third of the proteome is 
phosphorylated by only 518 kinases (Johnson & Hunter, 2005), and therefore that most 
kinases phosphorylate a multitude of substrates, it seems likely that these methods have 
fallen short of describing the breadth of PERK kinase activity.  
     The unbiased, chemical-genetic approach we describe here has provided a significant 
candidate substrate list from which to launch inquiry into novel signaling branches 
downstream of PERK. Confidence in these results has been increased through multiple 
biological replicates, as well as by the fact that two independent methods of substrate 
purification using the thiophosphoryl tag were employed. This has allowed us to identify 
overlap both within a single screening method, and between the two independent 
methods. Preliminary follow-up studies on four of the top candidates have verified 4/4, 
including the critical UPR mediators, ATF6 and IRE1. Future interrogation of these and 
other putative targets will elucidate the molecular details of known PERK signaling 
pathways, as well as uncover novel PERK networks and functions. 
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Figure 1.1 Signaling through the three branches of the Unfolded Protein Response. The ER stress 
sensors inositol-requiring gene 1 (IRE1), activating transcription factor 6 (ATF6), and (PKR)-like ER 
kinase (PERK) span the ER membrane. In response to conditions that perturb ER homeostasis, IRE1 is 
activated through oligomerization and trans-autophosphorylation. IRE1 RNase activity cleaves the mRNA 
of XBP-1 to generate an active transcription factor (XBP-1s) that targets genes involved in protein folding 
and ER-associated degradation to facilitate ER stress resolution and ultimately promote cell survival. 
Activation of ATF6 in response to ER stress involves its migration to the trans-Golgi, where it is 
proteolytically processed. This cleavage event releases the cytosolic bZIP domain, which translocates to the 
nucleus to activate the expression of ER chaperones and ERAD components. PERK activation occurs 
through oligomerization and trans-autophosphorylation, leading to phosphorylation of the translation 
initiation factor, eIF2α, and the antioxidant response factor, Nrf2. Phosphorylation of eIF2α leads to 
general inhibition of translation, contributing to overall cell survival. Phosphorylation of Nrf2 activates 
transcription of antioxidant factors. Selective upregulation of the bZIP transcription factor ATF4 through 
eIF2α targets both pro-survival genes as well as the pro-apoptotic factor GADD153/CHOP.  
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Figure 1.2 Oncogenic functions of PERK. Restricted nutrient and oxygen conditions in the tumor 
microenvironment triggers UPR signaling in cancer cells. The cell adaptive nature of PERK signaling 
enables enhanced cell survival, increased migratory and metastatic capacity, resistance to anoikis in ECM-
detached cells, and increased pro-angiogenic potential to support tumor growth. 
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Figure 1.3 Chemical-genetic approach to kinase inhibition. Generation of an analog-sensitive (AS) 
kinase involves mutation of the conserved gatekeeper residue in the ATP-binding pocket to a smaller amino 
acid. This creates a specificity pocket (red arrow) for binding bulky ATP analogs. ATP-competitive 
analogs with a bulky side chain will bind and inhibit the analog-sensitive kinase only; wild type kinases 
lacking the enlarged pocket will not accept the analog and thus will be unaffected in terms of activity. 
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Figure 1.4 Analog-sensitive kinases can be used for pathway mapping. The analog-sensitive kinase 
(AS) accepts an ATP analog that has been modified in two ways: first, by the addition of a bulky side chain 
and second, with the substitution of thiophosphate (*) in place of a phosphate group. While wild type 
kinases use ATP to phosphorylate substrates, the AS kinase uses bulky ATPγS to specifically label 
substrates with thiophosphate. This label can later be used to purify and identify substrates of the kinase of 
interest.
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CHAPTER TWO 
GENERATION AND CHARACTERIZATION OF AN ANALOG-SENSITIVE  
PERK ALLELE 
 
Nancy L. Maas, Nickpreet Singh, and J. Alan Diehl 
 
 
     Restriction of nutrients and oxygen in the tumor microenvironment disrupts ER 
homeostasis. Adaptation to this stress is mediated by the key UPR effector PERK, which 
is critical for tumor cell survival and growth. Given its protumorigenic activity, 
significant efforts have been made to elucidate the molecular mechanisms that underlie 
PERK function. Chemical-genetic approaches have recently proven instrumental in 
pathway mapping and interrogating kinase function. To enable a detailed study of PERK 
signaling we have generated an analog-sensitive PERK allele that accepts N6-alkylated 
ATP analogs. We find that this allele can be regulated by bulky ATP-competitive 
inhibitors, confirming the identity of the PERK gatekeeper residue as methionine 886. 
Furthermore, this analog-sensitive allele can be used to specifically label substrates with 
thiophosphate both in vitro and in cells. These data highlight the potential for using 
chemical-genetic techniques to identify novel PERK substrates, thereby providing an 
expanded view of PERK function and further definition of its signaling networks. 
 
 
 
 20 
2.1 Introduction 
     The tumor microenvironment is characterized by limitation of nutrients and oxygen, 
both of which are necessary for tumor expansion. These conditions arise from the 
combination of increased demand by proliferating tumor cells and compromised 
vasculature in surrounding tissue. One consequence of this environmental challenge is a 
reduced capacity for tumor cells to properly fold secretory proteins. The accumulating 
misfolded proteins trigger a cell adaptive response termed the Unfolded Protein Response 
(UPR). The pro-survival nature of this response is co-opted by cancer cells, allowing 
them to survive the harsh tumor microenvironment (Luo & Lee, 2013). 
     The UPR is mediated by three primary signal transducers: ATF6, Ire1, and PERK. 
These three factors are embedded in the ER membrane and act as ER stress sensors. 
Under homeostatic conditions, ATF6, Ire1, and PERK are bound by the ER luminal 
chaperone GRP78/BiP, preventing their activation (Bertolotti et al, 2000; Shen et al, 
2002). With ER stress, however, the accumulation of unfolded proteins increases demand 
for BiP chaperone function. This releases BiP, permitting oligomerization and activation 
of Ire1 and PERK, and migration of ATF6 to the trans-Golgi where it is proteolytically 
processed (Bertolotti et al, 2000; Shen et al, 2002).  The initial stages of this response are 
stress adaptive. To this end, activation of Ire1 and ATF6 upregulate ER chaperones to 
facilitate protein folding. Activation of PERK triggers eIF2α phosphorylation which 
inhibits protein synthesis, thus lowering the protein load (Harding et al, 1999; Shi et al, 
1998). In addition, eIF2α phosphorylation contributes to cell cycle arrest through 
inhibiting cyclin D1 translation. In turn, cell cycle arrest reduces cellular biosynthetic 
needs and thereby contributes to ER stress resolution (Brewer et al, 1999). PERK 
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signaling also selectively upregulates certain proteins, like the transcription factor ATF4. 
ATF4 regulates the expression of pro-survival genes that encode detoxifying enzymes as 
well as ER chaperones and foldases (Harding et al, 2003; Hetz et al, 2013). 
Paradoxically, ATF4 also increases expression of the pro-apoptotic transcription factor 
GADD153/CHOP after prolonged or acute ER stress, setting the stage for cell death 
(Tabas & Ron, 2011). 
     Consistent with the idea that the pro-survival effects of the UPR are important for 
tumor cell survival, key UPR mediators have been implicated in promoting tumorigenesis 
(Hetz et al, 2013; Ma & Hendershot, 2004). Among these is the primary UPR effector 
PERK, which has been characterized for its role in tumor growth, cell migration, 
metastasis, angiogenesis, survival of ECM-detached cells, and the epithelial-
mesenchymal transition (Avivar-Valderas et al, 2011; Bi et al, 2005; Blais et al, 2006; 
Bobrovnikova-Marjon et al, 2010; Feng et al, 2014; Mujcic et al, 2013; Nagelkerke et al, 
2013). In light of these pro-tumorigenic effects, there has been significant interest in 
developing cancer therapeutics that target PERK activity, and in defining the molecular 
mechanisms that underlie PERK function (Axten et al, 2012; Pytel et al, 2014).  
     To further interrogate PERK signaling networks, we have generated an analog-
sensitive PERK allele that specifically binds N6-alkylated ATP analogs. This involves 
mutation of a conserved residue in the ATP-binding pocket known as the “gatekeeper” 
(Bishop et al, 1998; Bishop et al, 2000). The gatekeeper residue blocks access to a deeper 
hydrophobic pocket; when mutated to a smaller amino acid, the resultant enlarged pocket 
specifically binds ATP analogs modified with a bulky alkyl group. Here, we show that 
analog-sensitive PERK alleles are specifically inhibited by bulky ATP-competitive 
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analogs, and that PERK M886A can utilize N6-alkylated ATPγS to label substrate both in 
vitro and in the context of permeabilized cells. These data highlight a strong potential for 
use of PERK M886A in network mapping. 
 
2.2 Results 
2.2.1 Methionine 886 is the gatekeeper residue 
     The gatekeeper residue for most protein kinases can be predicted through primary 
sequence alignment with related family members (Shokat & Velleca, 2002). To identify 
the gatekeeper residue for PERK, this alignment was performed through the Kinase 
Sequence Database (Buzko & Shokat, 2002). Conserved residues contacting ATP are 
represented in green, with the predicted residue for conferring analog sensitivity 
highlighted in red (Figure 2.1A). The predicted gatekeeper residue for PERK is 
methionine 886. To generate an analog-sensitive PERK allele, methionine 886 was 
mutated to three distinct small hydrophobic residues: glycine, alanine, and valine. To test 
whether M886 functions as the gatekeeper residue, recombinant wild type and mutant 
kinases were purified and used for radiometric in vitro kinase assays (Figure 2.1B). The 
p85 subunit of PI3K was used as substrate, as previous unpublished work from our lab 
revealed it to be a direct PERK substrate in vitro. We found that the three mutant PERK 
alleles retained varying degrees of kinase activity. Mutation of M886 to glycine severely 
crippled PERK activity, therefore, this mutant was not used for further study. M886V 
retained the highest level of kinase activity, and was thus considered the strongest 
candidate. In the presence of the bulky ATP-competitive inhibitor 1-NM-PP1, wild type 
kinase activity was unaffected, while all mutant alleles were inhibited both in terms of 
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PERK autophosphorylation and phosphorylation of p85 substrate. This suggests that 
mutation of M886 to a smaller amino acid opened an affinity pocket that allowed the 
bulky ATP analog to bind, confirming M886 as the gatekeeper residue. These results 
were verified for M886V by additional radiometric assays in which recombinant PERK 
was incubated with eIF2α substrate in the presence or absence of 1-NM-PP1 or another 
bulky ATP-competitive analog, 3-MB-PP1 (Figure 2.1C). 
2.2.2 PERK M886V and M886A are analog-sensitive in the context of cells 
     To assess kinase activity and our ability to regulate PERK gatekeeper mutants in vivo, 
PERK-/- embryonic fibroblasts were transduced with retrovirus encoding wild type 
PERK, PERK M886A or PERK M886V.  Stably transduced cell lines were subsequently 
challenged with thapsigargin to induce ER stress, in the presence or absence of the 
indicated doses of 3-MB-PP1. Consistent with in vitro results, the bulky ATP analog did 
not affect wild type PERK autophosphorylation or phosphorylation of eIF2α at any 
concentration tested (Figure 2.2A-B). PERK M886V exhibited sensitivity to 3-MB-PP1 
at concentrations between 20-40µM, with maximal inhibition at 100µM (Figure 2.2A). 
Of note, though this concentration did not affect wild type activity, it is well above the 
concentration of PP1 inhibitor generally used in cells (Au-Yeung et al, 2010; Levin et al, 
2008; Liu et al, 2009). In contrast, PERK M886A exhibited maximal sensitivity at 
significantly lower concentrations, suggesting that the alanine mutation permits more 
efficient analog binding (Figure 2.2B; data not shown). 
     To further characterize PERK M886A, effects on downstream signaling were assessed 
by stressing cells with thapsigargin for a more extended period to induce ATF4 and 
CHOP expression. 3-MB-PP1 inhibited PERK M886A and eIF2α phosphorylation as 
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well as ATF4 and CHOP induction, while having no influence on wild type activity 
(Figure 2.2C). Collectively, these data in vitro and in cells demonstrate that methionine 
886 is the PERK gatekeeper residue. Moreover, these studies suggest that mutation of 
M886 to alanine allows the highest binding affinity for PP1 inhibitors while retaining 
adequate kinase activity. 
2.2.3 3-MB-PP1 inhibits PERK activity, but exhibits previously uncharacterized off-
target effects 
     PERK is essential for cell survival following acute ER stress (Harding et al, 2000), 
therefore, we asked whether 3-MB-PP1 treatment impaired survival in cells expressing 
the PERK gatekeeper mutants. To address this, acute tunicamycin treatment was 
delivered in the presence or absence of 3-MB-PP1. Cells were also treated with the 
commercially available PERK inhibitor GSK2606414 (Axten et al, 2012) as a positive 
control. The outgrowth of colonies following ER stress was visualized by Giemsa 
staining. As anticipated, the control PERK inhibitor suppressed colony outgrowth, 
however, all cells regardless of genotype exhibited increased survival with 3-MB-PP1 
treatment (Figure 2.3A-B; data not shown). Given that PP1 inhibitors are known to be 
highly selective (Bishop et al, 2000), this off-target effect was surprising. Though this 
precludes further study of PERK function with 3-MB-PP1, the in vitro assays served to 
confirm the gatekeeper mutant and spur an effort to determine whether PERK M886A 
could be used as a tool for pathway mapping. 
2.2.4 PERK M886A can utilize bulky ATP analogs to label substrates in vitro 
     Chemical-genetic techniques have also been employed to map signaling networks 
through use of an analog-sensitive kinase that can specifically label substrates (Allen et 
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al, 2005; Allen et al, 2007; Banko et al, 2011; Blethrow et al, 2008). With this approach, 
the analog-sensitive kinase uses N6-alkylated ATPγS to transfer a thiophosphoryl group 
to its substrates. The bulky group again confers specificity for the analog-sensitive 
kinase, and the thiophosphoryl group acts as a label for distinguishing direct substrates 
from all other phosphorylated proteins in the cell. To determine whether PERK was able 
to use ATPγS as a phosphodonor, recombinant wild type PERK was incubated with 
eIF2α in the presence or absence of ATPγS. Reactions were alkylated and probed by 
western blot with an anti-thiophosphate ester antibody (Allen et al, 2005; Allen et al, 
2007) that recognizes alkylated, thiophosphorylated substrate (Figure 2.4A). PERK and 
eIF2α phosphorylation could be detected only in the presence of the ATPγS and the 
alkylating agent, PNBM, demonstrating not only that PERK can use ATPγS but that the 
thioP antibody is specific in this system. We then asked whether the M886A mutant 
could specifically use a bulky ATPγS analog to thiosphorylate substrate. In vitro kinase 
assays demonstrated that indeed, the gatekeeper mutant could use bulky and non-bulky 
ATPγS to label eIF2α, while wild type PERK could only use the non-bulky analog 
(Figure 2.4B). Furthermore, a comparison of various bulky analogs established N6-
furfuryl ATPγS as the preferred phosphodonor (Figure 2.4C). 
2.2.5 M886A thiophosphorylates substrate in permeabilized cells 
     Maintaining a kinase in its appropriate subcellular compartment is arguably the most 
desirable context for substrate labeling and identification. Therefore, we asked whether 
PERK could thiophosphorylate substrate under near-physiological conditions. This was 
addressed by gently permeabilizing cells expressing PERK wild type or M886A with a 
low concentration of digitonin. Cells were then incubated with thapsigargin in the 
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presence of N6-furfuryl ATPγS for in vivo substrate labeling. Analysis of whole cell 
lysates by western blot revealed increased thiosphorylation in the M886A mutant as 
compared to wild type (Figure 2.5A). Moreover, when labeled lysates were subjected to 
immunoprecipitation with the thioP antibody, increased labeling was again detected for 
M886A in enriched samples. To verify that the increase in signal was in fact dependent 
upon PERK kinase activity, cells were pre-treated with GSK2606414 prior to labeling. 
PERK inhibition decreased thiophosphorylation in the M886A-labeled sample to 
background levels, as seen in the PERK-/- and wild type lanes (Figure 2.5B). Together, 
these data reveal a strong potential for PERK M886A in screening for novel substrates.  
 
2.3 Discussion 
     To assess PERK function and identify novel signaling branches, we report an analog-
sensitive PERK allele, M886A, that is inhibited by the bulky ATP-competitive analog 3-
MB-PP1 both in vitro and in vivo. These results confirm methionine 886 as the 
gatekeeper residue for PERK. It is interesting to note, however, that our characterization 
of cellular responses to 3-MB-PP1 suggest an off-target activity of pyrazolo[3,4-
d]pyrimidine (PP) inhibitors that has not been previously reported. Not only did the PP1 
inhibitor enhance survival of the M886A mutant, which was the exact opposite of its 
anticipated effect, it also increased survival of cells expressing wild type PERK. 
Subsequent experiments performed by pulsing in 3-MB-PP1 at an even lower dose 
(5µM) recapitulated this result (data not shown). This could reflect inhibition of a stress 
induced pro-apoptotic pathway, or possibly activation of another UPR branch. Although 
we have not explored alternative inhibitors for use with M886A, several possibilities do 
 27 
exist for reducing off-target effects. Recent work from the Shokat lab proposed mutating 
the gatekeeper residue to cysteine for use with electrophilic inhibitors, a panel of which 
were screened for potency and specificity (Garske et al, 2011). These, in addition to a 
new set of inhibitors with even higher potency and selectivity (Zhang et al, 2013a) would 
provide a solid platform from which to launch such a study. 
     In terms of using the analog-sensitive version of PERK for novel substrate 
identification, the work presented here will be instrumental. To date, PERK substrate 
mapping has only been attempted via yeast two-hybrid screening (Cullinan et al, 2003).  
This study identified the antioxidant response factor Nrf2 as a direct PERK substrate, one 
of only three that have been identified thus far. We have shown that PERK M886A can 
label substrates with a unique thiophosphoryl tag, both in vitro and in permeabilized 
cells. This tag can subsequently be used for purification and mass spectrometry-based 
substrate identification. Moreover, the conditions have been optimized to allow substrate 
labeling in gently permeabilized cells, which should maintain PERK in its native 
subcellular compartment. This is arguably the most favorable condition for screening 
purposes, as it should reduce the number of false positives. In vivo labeling techniques 
have recently been used to successfully identify novel substrates of Erk2 and AMPK 
(Allen et al, 2007; Banko et al, 2011), giving us confidence in identifying PERK 
substrates in a similar fashion. Such a screen would provide significant information for 
understanding PERK signaling from a purely biological standpoint, and also may provide 
additional mechanistic data to consider for PERK inhibitor development in the treatment 
of cancer.  
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2.4 Materials and Methods 
2.4.1 Cell culture and treatments 
     Cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal bovine serum, 4mM L-glutamine, 55mM β-mercaptoethanol, and nonessential 
amino acids. To induce ER stress, cells were treated with 500nM thapsigargin (Sigma 
T9033) or 2.5ug/ml tunicamycin (Sigma T7765) for the indicated times. For PERK 
inhibition, cells were pre-treated with 1µM GSK2606414 (Axten et al, 2012) or the 
indicated concentrations of 3-MB-PP1 (EMD Millipore 529582) for 1 hr. 
2.4.2 Retroviral vectors and stable cell lines 
     Retroviral vectors for expression of PERK M886A and M886V were generated by 
QuikChange site-directed mutagenesis (Agilent 200521) of Myc-tagged full-length 
mPERK in pBabe-puro. Stable cell lines were generated by transducing PERK-/- mouse 
embryonic fibroblasts (Gao et al, 2012) with retrovirus carrying these constructs. Cells 
were selected with and maintained in 5ug/ml puromycin. 
2.4.3 Antibodies and immunoblotting 
     Cells were lysed in EBC buffer (50  mM Tris pH 8.0, 120  mM NaCl, 0.5% NP-40) or 
RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1.0% NP-40, 0.1% SDS) supplemented 
with protease and phosphatase inhibitors. The following antibodies were used for 
immunoblotting: anti-PERK (Cell Signaling 3192), anti-phosphoserine 51 of eIF2α (Cell 
Signaling 3597), anti-CHOP (Cell Signaling 2895), anti-eIF2α (Invitrogen AHO0802), 
anti-ATF4 (Santa Cruz Biotechnology sc-200), anti-lamin B (Santa Cruz Biotechnology 
sc-6216), anti-beta actin (Sigma A5441). The thioP antibody has been previously 
described (Allen et al, 2005; Allen et al, 2007) and was available from Epitomics/Abcam 
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(ab92570). 
2.4.4 Radiometric in vitro kinase assay 
     PERK M886G, M886A, and M886V were generated by QuikChange site-directed 
mutagenesis (Agilent 200521) of GST-tagged PERK-ΔN in pGEX (Bobrovnikova-
Marjon et al, 2012). Recombinant PERK was expressed in BL21 bacterial cells and 
purified using GST Purification columns (Clontech 635619). HIS-tagged eIF2α in 
pET15b was expressed in BL21(DE3) cells and purified on HisTALON gravity columns 
(Clontech 635654). Recombinant p85 was from SignalChem (P31-30H). PERK was pre-
treated with indicated concentrations of 1-NM-PP1 (EMD Millipore 529581) or 3-MB-
PP1 (EMD Millipore 529582) for 30 min. PERK was then incubated with recombinant 
substrate in the presence of γ-32P-ATP for an additional 30 min at 30°C. Reactions were 
run on an SDS-PAGE gel, Coomassie-stained for loading, and exposed to film. 
2.4.5 ATPγS in vitro kinase assay 
     Recombinant GST-tagged PERK-ΔN (described above) was incubated with 
recombinant eIF2α in the presence of 1mM ATPγS (Biolog A060) or N6-substituted 
ATPγS (Biolog F008, B072, P026) for 30 min at 30°C (Hertz et al, 2010). Following 
thiophosphorylation, reactions were alkylated by adding p-nitrobenzyl mesylate (Abcam 
ab138910) to 2.5mM for 1 hr at room temperature. Samples were boiled in SDS sample 
buffer, run on an SDS-PAGE gel, and probed by western blot for thiophosphorylated 
protein.  
2.4.6 Fractionation 
     Cells were lysed in 6 pellet volumes Harvest Buffer (10mM HEPES pH 7.9, 50mM 
NaCl, 0.5M sucrose, 0.1mM EDTA, 0.5% Triton X 100) supplemented with 1mM DTT, 
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and protease and phosphatase inhibitors. Nuclei were pelleted, washed in Buffer A 
(10mM HEPES pH 7.9, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA), and lysed in 4 
volumes Buffer C (10mM HEPES pH 7.9, 500mM NaCl, 0.1mM EDTA, 0.1mM EGTA, 
0.1% NP-40). Nuclei were vortexed for 15 min at 4°C and clarified. Cytoplasmic and 
nuclear extracts were analyzed by western blot. 
2.4.7 In vivo substrate labeling and immunoprecipitation 
     Samples were prepared as previously described (Allen et al, 2007) with slight 
modifications. In brief, cells were trypsinized, counted, and resuspended to 3x106 cells/ml 
in cold kinase buffer (25mM Tris pH 7.5, 10mM MgCl2 in PBS) and 50ug/ml digitonin 
to permeabilize. Cells were incubated on ice for 5 min, pelleted gently, then resuspended 
in kinase buffer containing 500nM thapsigargin, 100µM N6-furfuryl ATPγS (Biolog 
F008), and 1mM GTP (Sigma G8877) for substrate labeling. Cells were incubated for 1 
hr at 30°C with gentle shaking, then lysed in RIPA buffer (50 mM Tris pH 8, 150 mM 
NaCl, 1.0% NP-40, 0.1% SDS) containing 25mM EDTA to quench. Lysates were 
alkylated by adding p-nitrobenzyl mesylate (Abcam ab138910) to 2.5mM for 1 hr at 
room temperature with nutation. For immunoprecipitation, lysates were exchanged to 
RIPA buffer on PD Miditrap G-25 columns (GE Healthcare 28-9180-08) to remove 
PNBM. Lysates were then pre-cleared with rProtein G agarose (Invitrogen 15920-010) 
and subjected to immunoprecipitation with thioP antibody bound to rProtein G agarose 
beads.  
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2.4.8 Cell survival after ER stress 
     Cells were seeded at 20,000 per 60mm dish and pre-treated with indicated doses of 3-
MB-PP1 for 1 hr. Cells were then challenged with an acute dose of tunicamycin 
(2.5ug/ml) for 30 min. Colony outgrowth was assessed by Giemsa staining after 6 days. 
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Figure 2.1 The gatekeeper residue for PERK is methionine 886. (A) Sequence alignment of the PERK 
ATP-binding pocket with related kinases predicts the conserved gatekeeper residue, shown in red. (B) PP1 
inhibitors inhibit the gatekeeper mutant in vitro. Recombinant WT PERK-ΔN or PERK-ΔN M886G/A/V 
were pre-incubated with 1-NM-PP1. Kinase was then incubated alone (-) or with p85 substrate in the 
presence of γ-32P-ATP. Reactions were run on an SDS-PAGE gel and exposed to film. Western blots were 
performed against total levels to confirm equal loading (Ponceau stains for p85 shown for M886A, 
M886V). (C) Recombinant WT PERK-ΔN and PERK-ΔN M886V were pre-incubated with 1-NM-PP1 
(NM) or 3-MB-PP1 (MB). Kinase was then incubated with recombinant eIF2α in the presence of γ-32P-
ATP. Reactions were run on an SDS-PAGE gel and exposed to film.  
B 
A 
C 
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Figure 2.2 Analog-sensitive PERK alleles are functional in the context of cells. (A) 3-MB-PP1 inhibits 
PERK M886V. PERK-/- mouse fibroblasts expressing PERK WT or M886V were pre-treated with the 
indicated doses of 3-MB-PP1, then challenged with thapsigargin (TG) for 1 hr. PERK activation was 
assessed by western blot for PERK and eIF2α phosphorylation. (B) 3-MB-PP1 inhibits PERK M886A. 
PERK-/- mouse fibroblasts expressing PERK WT or M886A were treated as described in (A). (C) Cells 
were pre-treated with the indicated doses of 3-MB-PP1, then challenged with TG for 4 hr to induce ATF4 
and CHOP expression. Cytoplasmic fractions were probed for PERK and p-eIF2α, with total eIF2α to 
control for equal loading. Nuclear fractions were probed for ATF4 and CHOP, with lamin B as a loading 
control. 
B 
A 
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Figure 2.3 3-MB-PP1 rescues tunicamycin-sensitivity in wildtype cells, demonstrating an off-target 
effect. (A) Immortalized PERK-/- mouse fibroblasts stably expressing wild type PERK were pre-treated 
with 10µM (bottom, left) or 15µM (bottom, right) 3-MB-PP1 for 1h, or with GSK2606414 as a control. 
Cells were then acutely stressed with tunicamycin for 30 min and allowed to grow for 6 days. Colonies 
were stained with Giemsa. (B) Cells of the indicated genotypes were pre-treated with 10µM 3-MB-PP1 for 
1h, then treated as described in (A). 
A 
B 
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Figure 2.4 PERK M886A can utilize bulky ATPγS to thiophosphorylate substrate in vitro. (A) The 
thioP antibody specifically recognizes alkylated, thiophosphorylated PERK substrate. Recombinant WT 
PERK-ΔN was incubated with eIF2α in the presence or absence of 1mM ATPγS or ATP. Samples were 
alkylated (PNBM) and assessed by western blot for thiophosphorylated protein using an anti-thiophosphate 
ester antibody (α-thioP). (B) Only PERK M886A can use bulky ATPγS to thiophosphorylate substrate in 
vitro. Recombinant WT or M886A PERK-ΔN was incubated with eIF2α in the presence of ATPγS or 
benzyl (Bn) ATPγS. Reactions were alkylated, then and probed by western blot with the thioP antibody. 
(C) PERK M886A prefers N6-furfuryl ATPγS. Recombinant WT or M886A PERK-ΔN were used in 
kinase assays, as described in (B) with the inclusion of the indicated bulky ATPγS analogs.  
B 
A 
C 
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Figure 2.5 PERK M886A thiophosphorylates substrate in permeabilized cells. (A) PERK-/- cells 
expressing either PERK WT or M886A were permeabilized, then incubated with thapsigargin and N6-
furfuryl ATPγS for substrate labeling. Cells were lysed, and lysates alkylated. Lysates were probed by 
western blot for total thiophosphorylated substrate (left). Alkylated lysates were then immunoprecipitated 
with α-thioP (right). (B) Cells expressing M886A were pre-treated with GSK2606414 inhibitor as a control 
for PERK-dependent activity. The indicated cell types were then treated as described in (A).  
B A 
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CHAPTER THREE 
A CHEMICAL-GENETIC SCREEN FOR PERK SUBSTRATE IDENTIFICATION 
 
Nancy L. Maas, Rebecca Levin, Kevan M. Shokat, and J. Alan Diehl 
 
 
     The ER kinase PERK, a key mediator of the Unfolded Protein Response, is known to 
promote tumorigenesis, cell migration, and metastasis, as well as inhibit anoikis. Though 
PERK has these and other important cellular functions, only a handful of its direct 
substrates are currently known. Therefore, in order to provide an expanded view of 
PERK function and further definition of its signaling networks, we have used a chemical-
genetic approach to screen for additional PERK substrates. We find that a mutation in the 
PERK ATP binding pocket renders it sensitive to bulky ATP analogs both in vitro and in 
cells. Furthermore, bulky ATPγS analogs were used exclusively by the analog-sensitive 
version of PERK to label substrates with thiophosphate. After labeling, 
thiophosphorylated substrates were affinity purified by immunoprecipitation or 
thiophosphopeptide capture, and subsequently identified by tandem mass spectrometry. 
Utilization of this analog-sensitive PERK allele for substrate characterization will be 
discussed. 
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3.1 Introduction 
     It is estimated that approximately one-third of all intracellular proteins are 
phosphorylated (Johnson & Hunter, 2005), making phosphorylation the most common 
signaling mechanism for regulating protein function and activity. Protein kinases are 
responsible for mediating this modification through transfer of a phosphate group from 
ATP to serine, threonine, or tyrosine of its substrates. Phosphorylation induces a 
conformational change that affects either the protein’s catalytic activity, or creates a 
binding motif for interacting proteins. This modification is reversible; the removal of 
phosphate is catalyzed by protein phosphatases. This quality of reversibility is essential 
for the dynamic nature of cellular response to internal and external stimuli, i.e. for signal 
transduction. 
     Chemical-genetic techniques have recently been at the forefront of kinomics, or the 
global study of kinase signaling. In contrast to more traditional methods for substrate 
identification, this approach can be used to identify direct kinase-substrate relationships 
in a large-scale setting. Initial studies utilized an analog-sensitive allele of Cdk1 (Cdk1-
as1) that was engineered to accept a bulky, radiolabeled ATP analog (Ubersax et al, 
2003). Cdk1-as1 catalyzed transfer of the radiolabel to substrates in a library of affinity-
tagged yeast proteins, which were then purified and assessed for phosphorylation. By this 
method, over 200 Cdk1 substrates were identified. For mammalian systems, however, 
such libraries do not yet exist. It was therefore necessary to design a strategy for 
transferring an affinity tag to substrates that could later be used for purification and 
substrate identification. To this end, Shokat and colleagues devised a system wherein an 
analog-sensitive kinase could instead transfer a thiophosphate group from a bulky ATPγS 
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analog to substrates (Allen et al, 2007; Blethrow et al, 2008). This thiophosphate could 
later be used as a “handle” for purification and identification by mass spectrometry.  
     With regard to PERK signaling, only one screen has thus far been performed for 
substrate identification (Cullinan et al, 2003), with just three direct PERK substrates 
identified to date: the translation initiation factor eIF2α (Harding et al, 1999; Shi et al, 
1998), the antioxidant response factor Nrf2 (Cullinan et al, 2003), and most recently, the 
FOXO transcription factor (Zhang et al, 2013b). Further elucidation of PERK signaling 
networks is therefore in order. As described in Chapter 2, we have generated and 
thoroughly characterized an analog-sensitive PERK allele that can specifically transfer 
thiophosphate from N6-alkylated ATPγS to eIF2α substrate in vitro. Furthermore, we 
have demonstrated that substrate labeling can be conducted in the context of intact cells, 
allowing PERK to remain in its native compartment during this process. Here we present 
the results of a chemical-genetic screen for PERK substrates, with substrate identification 
performed by two methods. Interestingly, the screen results suggest crosstalk between 
PERK and the two other major branches of the UPR: ATF6 and IRE1. Two additional 
novel substrates, VAPB and EEF1D, have also been verified in vitro, with a significant 
list of candidates yet to be explored. 
 
3.2 Results 
3.2.1 In vivo substrate labeling followed by immunoprecipitation and mass 
spectrometry identifies 607 candidate substrates 
     The chemical-genetic PERK substrate screen was designed utilizing the previously 
characterized analog-sensitive allele, PERK M886A (Maas et al, 2014). As demonstrated 
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in the previous work, the optimal ATP analog for use by PERK M886A is N6-furfuryl 
ATPγS. We then sought to optimize labeling conditions, i.e. to determine the optimal 
length of incubation with ATP analog that would achieve maximal thiophosphoryl 
labeling in the M886A sample with minimal background signal in PERK-/- and wild type 
samples. To address this, immortalized mouse embryonic fibroblasts transduced to stably 
express either wild type or M886A PERK were gently permeabilized and incubated with 
the bulky ATP analog, N6-furfuryl ATPγS in the presence of thapsigargin to induce ER 
stress. Cells were then lysed and assessed for total thiophosphorylated substrate by 
western blot (Figure 3.1). We found that cells incubated with ATP analog for 1h resulted 
in a significant increase in thiophosphorylated protein over the 0.5h labeling time. 
Incubation for 1.5h did not increase this signal, therefore the 1h time point was used for 
substrate labeling for the screen. Importantly, all samples exhibited minimal substrate 
labeling in PERK-/- and wild type cells. 
     For screening purposes, the scale of the labeling experiment was increased 
significantly, then one of two substrate identification methods was employed (Figure 
3.2). The first method involved alkylation of thiophosphorylated proteins, followed by 
affinity purification of labeled proteins with an antibody that recognizes the alkylated, 
thiophosphorylated moiety. Labeling efficiency was verified prior to 
immunoprecipitation by western blot; a stronger signal confirmed more efficient substrate 
labeling by PERK M886A compared with wild type (Figure 3.3A, left). Following 
immunoprecipitation with the α-thioP antibody, samples were run on an SDS-PAGE gel 
and silver-stained to reveal thiophosphorylated proteins (Figure 3.3A, right). Mass 
spectrometric analysis of silver-stained gel slices identified over 600 proteins specifically 
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found in the samples labeled by the analog-sensitive kinase and not in the wild type 
samples. Only those proteins that were detected at 5 peptides or greater were considered 
for this list. 
     The candidate list was subsequently sorted by GO term and assessed for enrichment 
over reference set (Figure 3.3B) using GOToolbox (Martin et al, 2004). We found 
significant enrichment of metabolic pathway categories, which is consistent with the role 
of PERK in lipid and glucose metabolism. Also in line with known PERK functions were 
GO categories related to transport, specifically, vesicle-mediated and transmembrane 
transport. Interestingly, both ATF6α and ERN1/IRE1, the master regulators of the other 
UPR branches were thiophosphorylated in the analog-sensitive kinase samples alone. 
This is intriguing in that it suggests a novel mode of crosstalk between the three main 
UPR pathways. 
3.2.2 ATF6α  and IRE1 are candidate PERK substrates. 
     Though the idea of integrated signaling between UPR pathways has been proposed, no 
direct interaction between PERK and ATF6 or IRE1 has yet been shown. There is, 
however, evidence that PERK activation occurs prior to ATF6 and IRE1 (Rutkowski & 
Kaufman, 2004), and that PERK is required for full ATF6 activation (Teske et al, 2011). 
These, together with the fact that activated PERK is in close proximity to both ATF6 and 
IRE1, are consistent with the idea that PERK could play a role in full activation of the 
remaining UPR branches. 
     To independently confirm results from the screen, substrate thiophosphorylation was 
performed in permeabilized cells stably expressing either wild type or M886A PERK, 
and transfected to overexpress a tagged form of either ATF6 or IRE1. Increased substrate 
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labeling was observed in cells expressing PERK M886A (Figure 3.4A). Candidate 
substrates were subsequently immunoprecipitated and assessed for thiophosphorylation. 
Both IRE1 (Figure 3.4B) and ATF6 (Figure 3.4C) were again specifically phosphorylated 
in cells expressing PERK M886A, confirming the results of the screen for these two 
candidates. 
     To verify that ATF6 and IRE1 could be directly phosphorylated by PERK, in vitro 
kinase assays were performed. Tagged forms of both proteins were expressed in 293T 
cells and immunoprecipitated for use as substrate in vitro. Incubation of substrate with 
recombinant PERK in the presence of ATPγS was followed by analysis of 
thiophosphorylated protein by western blot. We found that ATF6 was directly 
phosphorylated by PERK in vitro (Figure 3.5, left), which led us to ask whether the site 
of phosphorylation could also be determined. To address this, scaled-up kinase assays 
were performed, and reactions were run on an SDS-PAGE gel for silver staining and 
analysis by mass spectrometry (Figure 3.5, right). Though the sequence coverage was 
close to 50% overall, tryptic digest did not produce many suitable peptides for the N-
terminal half, the cytosolic region of ATF6 that would most likely be phosphorylated by 
PERK. We feel confident that chymotryptic digest of a 5-fold increased reaction would 
yield the desired result. 
     Results for IRE1 were inconclusive as recombinant PERK and immunoprecipitated 
IRE1 were of nearly identical molecular weight (data not shown). Further optimization 
(e.g. utilizing a C-terminal fragment of recombinant IRE1 in place of full-length) will 
therefore be required to determine whether IRE1 is a direct PERK target.  
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3.2.3 In vivo substrate labeling followed by thiophosphopeptide capture identifies 35 
candidate substrates with phospho-sites. 
     As an independent method of confirming results from the primary screen and culling 
the large list of candidate substrates, a second method for PERK substrate identification 
was employed (Hertz et al, 2010). This method involves digestion of thiophosphorylated 
proteins to peptides, which are then affinity purified on iodoacetyl beads. After 
purification, peptides are specifically released by oxone treatment. This system has the 
advantage of providing not only a list of candidate substrates, but also identifying the 
sites of phosphorylation. Incorporated into this screen was an additional control: substrate 
labeling in the absence of PERK.  
     We found that labeling efficiency was higher in PERK M886A samples than in 
PERK-/- or cells expressing wild type PERK, as anticipated (Figure 3.6). Three 
independent large-scale labeling experiments were performed, followed by 
thiophosphopeptide capture to generate a candidate substrate list of 35 proteins with 
defined phospho-sites (Table 3.1). These proteins were only considered candidate 
substrates if detected in the M886A sample alone, a stringent cutoff for the screen. Of 
these, over half were ER-associated, including PERK itself which we anticipated to be 
autophosphorylated. To determine whether there were putative substrates identified by 
both immunoprecipitation/MS and peptide capture/MS, overlap between datasets was 
assessed (Table 3.2). We found that 9/35 of the substrates identified here were also found 
in the larger dataset described in 3.2.1. In terms of overlap between the three peptide 
capture replicates, 5/35 were repeatedly represented. Of immediate interest were two of 
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the candidate substrates: eukaryotic elongation factor 1-delta (EEF1D), and vesicle-
associated membrane protein-associated protein B/C (VAPB).  
3.2.4 PERK phosphorylates EEF1D on serine 162. 
     General translation is rapidly attenuated with PERK activation; this has previously 
been attributed solely to PERK-dependent phosphorylation and inhibition of the 
eukaryotic translation initiation factor, eIF2α. This does not, however, preclude the 
possibility that concomitant inhibition of the translation elongation factor eEF1D by 
PERK could also serve to facilitate this response. In fact, studies of translational 
repression mechanisms during mitosis support the idea that translation is tightly regulated 
not only at the initiation stage but also during elongation (Sivan et al, 2007).  
     eEF1D is the catalytic delta subunit of eEF1B, a multi-subunit guanine exchange 
factor (GEF) that facilitates the exchange of GDP for GTP on eEF1A. During mitosis, 
CDK1-mediated phosphorylation of eEF1D on serine 133 inhibits the interaction between 
eEF1B and eEF1A (Sivan et al, 2011). This slows tRNA delivery to ribosomes, thus 
contributing to translational repression. eEF1D has also been previously identified as a 
substrate of casein kinase II (CK2) (Gyenis et al, 2011; Palen et al, 1994; Sheu & Traugh, 
1997; Sheu & Traugh, 1999). Gyenis et al identified eEF1D as a protein that exhibited 
decreased phosphorylation in cells treated with CK2 inhibitors as well as cells depleted 
for CK2. Furthermore, CK2 has been shown to directly phosphorylate eEF1D on serine 
162 (Gyenis et al, 2011; Sheu & Traugh, 1999), which is the PERK-mediated phospho-
site identified in our study. 
     To determine whether PERK directly phosphorylates eEF1D, in vitro kinase assays 
were performed (Figure 3.7). Recombinant PERK was incubated with 
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immunoprecipitated eEF1D wild type or S162A mutant in kinase buffer supplemented 
with ATP. Reactions were then assessed for eEF1D S162 phosphorylation by western 
blot using a phospho-specific antibody (Gyenis et al, 2011). We found that PERK 
directly phosphorylated wild type eEF1D, but that this event was abrogated when the 
S162A mutant was used as substrate. This demonstrates that eEF1D is directly 
phosphorylated by PERK on serine 162 in vitro, validating the result from our screen.  
3.2.5 PERK phosphorylates VAPB in vitro. 
     Vesicle-associated membrane protein-associated protein B/C (VAPB/ALS8) was also 
identified as a putative PERK substrate, with phosphorylation detected on threonine 148. 
VAPB is a member of the VAP family, which was originally studied for its role in 
neurotransmitter exocytosis (Skehel et al, 1995) and has since been identified as an 
integral membrane protein of the ER, and mediator of the UPR (Kagiwada et al, 1998; 
Kanekura et al, 2006). Moreover, VAPB has been implicated in regulating ER structure 
through interaction with Nir proteins, ER-Golgi trafficking, and regulation of 
phopholipids (Amarilio et al, 2005; Peretti et al, 2008). A role for VAPB is also 
suggested in ER protein quality control (ERQC), with its loss resulting in protein 
accumulation, ER expansion, and ER stress (Moustaqim-Barrette et al, 2014). These 
significant functions of VAPB in the context of ER stress make it a prime candidate for 
further investigation as a putative PERK target.  
     To determine whether PERK directly phosphorylates VAPB, recombinant PERK was 
incubated with recombinant human VAPB in the presence of the non-bulky ATP analog, 
ATPγS for substrate labeling (Figure 3.8). Following alkylation, reactions were probed 
by western blot for thiophosphorylated substrate. We found that only in the presence of 
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VAPB, kinase and ATPγS was a band between 25-37 kDa detected. This was previously 
determined by Coomassie stain to be the molecular weight of recombinant VAPB (data 
not shown). These data confirm VAPB as a PERK substrate in vitro. Though the 
phospho-site has not yet been tested, a VAPB T148A phospho-mutant will determine 
whether this modification is as predicted by our screen. 
   
3.3 Discussion 
     In the present study, we have successfully designed and implemented a chemical-
genetic screen for PERK substrate identification. This screen was optimized for substrate 
labeling in vivo, which should maintain PERK in its native compartment, thereby 
decreasing the number of spurious positives. Two independent methods of substrate 
identification have generated candidate lists of 35 and 607 putative substrates. We have 
begun to verify individual candidates, and three of the four tested thus far have been 
confirmed for direct phosphorylation by PERK in vitro. These putative substrates (ATF6, 
eEF1D, and VAPB) are ER-associated proteins that have either demonstrated influence 
on UPR signaling and/or seem likely to mediate downstream PERK functions.  
     Though we report a high number of candidate substrates that are ER-associated, and 
have detected PERK thiophosphorylation exclusively and consistently in samples labeled 
by the analog-sensitive kinase, we have not yet been able to detect thiophosphorylation of 
the three known PERK substrates (eIF2α, Nrf2, and FOXO). To further pursue this type 
of screen validation, we have assessed eIF2α immunoprecipitated from labeled lysates 
for evidence of thiophosphorylation. Again, we have not been able to detect this 
modification. We are therefore unable to definitively state that within the setting/ 
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conditions of our screen, PERK M886A targets its native substrates. One explanation for 
our failure to detect eIF2α thiophosphorylation is fact that a large pool of eIF2α is 
rapidly phosphorylated within minutes after ER stress induction (data not shown). It is 
therefore possible that PERK M886A phosphorylates the majority of eIF2α prior to the 
influx of bulky ATPγS during substrate labeling. Alternatively, our system could be 
saturated by newly-identified substrates that are more readily labeled or purified. The 
abundance of unlabeled protein in the cell could also mask labeled substrate of lower 
abundance. Overall screen sensitivity would then be improved through additional 
phosphopeptide enrichment steps. Finally, it remains possible that cell treatments 
incorporated into our screen such as trypsinization and permeabilization have drawn 
PERK M886A away from its natural targets. We have shown, however, that in the same 
cell lines used for the screen, signaling downstream of PERK M886A remains intact 
(Maas et al, 2014), increasing our confidence in screen integrity. 
      In terms of prioritizing candidates for follow-up study, the list of ~600 proteins will 
present a challenge. This list was generated through immunoprecipitation, which could be 
optimized with more stringent wash conditions if additional biological replicates are 
attempted. Sodium dodecyl sulfate (SDS) was used in the lysis buffer prior to 
immunoprecipitation, however, its concentration could also be increased to facilitate 
disruption of complexes. In its current state, the large list of substrates can be sorted into 
categories of particular interest for follow-up, e.g. the UPR-related category that includes 
ATF6, IRE1, and SREBP2. The nine proteins that overlap with the smaller dataset should 
also be prioritized. 
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     In summary, this work has provided a platform from which to explore the mechanistic 
details of PERK signaling through both known and novel networks. The identification of 
IRE1 and ATF6, for instance, suggests an intriguing possibility of direct crosstalk 
between UPR branches through PERK-mediated phosphorylation. Assuming that these 
results are confirmed in vivo, it will be interesting to ask whether PERK-dependent 
crosstalk is a major determinant in fine-tuning the ER stress response, i.e. in regulating its 
intensity and attenuation as well as differential activation of the three branches. Also 
significant is the identification and in vitro confirmation of eEF1D phosphorylation. Thus 
far, relatively little is known about its phosphorylation on serine 162 with regard to 
function. If eEF1D phosphorylation results in dissociation of the eEF1A/eEF1B complex 
or a decrease in eEF1B catalytic activity, this modification would serve to inhibit 
translation in the face of ER stress. Finally, the identification and verification of VAPB 
proposes a possible mechanistic link between PERK, phospholipid regulation, and 
maintenance of ER-Golgi structure. This is particularly interesting in light of the recently 
defined role for PERK as a lipid kinase (Bobrovnikova-Marjon et al, 2012). Additional in 
vitro experiments will be required to identify phospho-sites for candidates of interest 
generated by thioP immunoprecipitation/MS, and further interrogation of all candidates 
in cells and perhaps in vivo will be necessary for determining whether the detected 
phosphorylation events contribute to PERK function in ER stress signaling. 
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3.4 Materials and Methods 
3.4.1 Cell culture  
     Immortalized mouse embryonic fibroblasts were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, 4mM L-glutamine, 55mM 
β-mercaptoethanol, nonessential amino acids, and penicillin-streptomycin. HEK293T 
cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum and penicillin-streptomycin.   
3.4.2 Stable cell lines 
     Cell lines excised for PERK and transduced to stably express wild type or M886A 
PERK were described previously (Gao et al, 2012; Maas et al, 2014). Cells were selected 
and maintained in 5ug/ml puromycin. 
3.4.3 Antibodies and affinity resins 
     The following antibodies were used for immunoblotting: anti-IRE1 (Cell Signaling 
3294S), anti-FLAG (Sigma F1804), anti-PERK (Cell Signaling 3192) and anti-beta actin 
(Sigma A5441). The thioP antibody has been previously described (Allen et al, 2005; 
Allen et al, 2007) and was available from Epitomics/Abcam (ab92570). The phospho-
EEF1D S162 antibody was a generous gift from Dr. David Litchfield, and has been 
previously described (Gyenis et al, 2011).  
3.4.4 Recombinant proteins and expression constructs 
     Recombinant GST-tagged PERK-ΔN was expressed in BL21 bacterial cells and 
purified using GST Purification columns (Clontech 635619). Human recombinant VAPB 
was purchased from ProSpec (PRO-014). ATF6 was expressed from p3xFLAG-ATF6 
(S1P-), which was a kind gift from Dr. Ron Prywes. IRE1 was expressed from pCAX 
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IRE1α-HA-K599A, which was generated by Dr. Zhenhua Xu through Quikchange 
mutagenesis using pCAX IRE1α-HA from Dr. Takao Iwawaki. Expression constructs for 
FLAG-tagged EEF1D wild type and S162A were generous gifts from Dr. David 
Litchfield, and have been previously described (Gyenis et al, 2011). 
3.4.5 ATPγS in vitro kinase assay (ATF6 and VAPB) 
     Recombinant GST-tagged PERK-ΔN was incubated with substrate in the presence of 
1mM ATPγS (Biolog A060) for 30 min at 30°C (Hertz et al, 2010). Following 
thiophosphorylation, reactions were alkylated by adding p-nitrobenzyl mesylate (Abcam 
ab138910) to 2.5mM for 1 hr at room temperature. Samples were boiled in SDS sample 
buffer, run on an SDS-PAGE gel, and probed by western blot for thiophosphorylated 
protein.  
3.4.6 In vitro kinase assay for EEF1D 
     FLAG-tagged EEF1D wild type and S162A were immunoprecipitated from 293T cells 
with anti-FLAG M2-Agarose Affinity Gel (Sigma A2220). EEF1D substrate (on beads) 
was incubated with  recombinant GST-tagged PERK-ΔN in kinase buffer for 30 min at 
30°C. Samples were boiled in SDS sample buffer, run on an SDS-PAGE gel, and probed 
by western blot for EEF1D phosphorylated on S162 with a phospho-specific antibody 
(Gyenis et al, 2011). 
3.4.7 In vivo substrate labeling and immunoprecipitation for mass spec analysis 
     Samples were prepared as previously described (Allen et al, 2007) with slight 
modifications. In brief, 5x107 cells expressing wild type or M886A PERK were 
trypsinized, counted, and resuspended to 3x106 cells/ml in cold kinase buffer (25mM Tris 
pH 7.5, 10mM MgCl2 in PBS) and 50ug/ml digitonin to permeabilize. Cells were 
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incubated on ice for 5 min, pelleted gently, then resuspended in kinase buffer containing 
500nM thapsigargin, 100µM N6-furfuryl ATPγS (Biolog F008), and 1mM GTP (Sigma 
G8877) for substrate labeling. Cells were incubated for 1 hr at 30°C with gentle shaking, 
then lysed in RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1.0% NP-40, 0.1% SDS) 
containing 25mM EDTA to quench. Lysates were alkylated by adding p-nitrobenzyl 
mesylate (Abcam ab138910) to 2.5mM for 1 hr at room temperature with nutation. For 
immunoprecipitation, lysates were exchanged to RIPA buffer on PD Miditrap G-25 
columns (GE Healthcare 28-9180-08) to remove PNBM. For immunoprecipitation of 
thiophosphorylated proteins followed by mass spectrometry, lysates were pre-cleared 
with rProtein G agarose (Invitrogen 15920-010) and subjected to immunoprecipitation 
with thioP antibody bound to rProtein G agarose beads overnight. Immunoprecipitates 
were run on an SDS-PAGE gel and stained with Pierce Silver Stain Kit for Mass 
Spectrometry (Pierce 24600). Mass spectrometry was performed by the Taplin Mass 
Spectrometry Facility at the Harvard Medical School. For immunoprecipitation of 
candidate PERK substrates, lysates were incubated with either anti-FLAG M2-Agarose 
Affinity Gel (Sigma A2220) or Monoclonal Anti-HA Agarose (Sigma A2095). 
3.4.8 Thiophosphopeptide capture 
     5x107 PERK-/- cells or cells expressing either wild type or M886A PERK were 
labeled in vivo as described in 3.4.6. Cells were then resuspended in RIPA buffer lacking 
SDS and sonicated for complete lysis. Lysates were prepared for thiophosphopeptide 
capture as previously described (Hertz et al, 2010). Mass spectrometry was performed at 
the University of California San Francisco. Results from three independent large-scale 
experiments were compiled for the list of candidate substrates presented.  
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3.4.9 Bioinformatic analysis of gene dataset generated by immunoprecipitation/MS 
     Following the procedure described in 3.4.7, the resultant list of proteins 
immunoprecipitated with the thioP antibody was culled according to number of peptides 
detected. Only proteins that were represented at 5 peptides or greater were retained. 
Candidates were then assigned GO terms and assessed for enrichment of GO categories 
over reference set using GOToolBox (Martin et al, 2004). Reference set used was the 
mouse genome, ontology was set to Biological Process, and term filtering at level 3.  
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Figure 3.1  Optimization of labeling time for PERK substrate screen. Immortalized mouse embryonic 
fibroblasts expressing either PERK wild type or M886A were gently permeabilized, then incubated with 
thapsigargin and N6-furfuryl ATPγS for substrate labeling. Lysates were alkylated, assessed for labeling 
efficiency by western blot (left),
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Figure 3.2  Chemical-genetic substrate labeling and identification strategies. Analog-sensitive PERK 
has been engineered with a novel specificity pocket in the ATP-binding site that allows it to accept bulky 
ATP analogs carrying a thio-phosphate label (*). The thio-phosphate group is then transferred specifically 
to PERK substrates in intact cells. The first method for substrate identification (left) involves alkylating 
labeled substrates with p-nitrobenzyl mesylate and immunoprecipitating with an antibody that recognizes 
alkylated, thio-phosphorylated protein. Substrates are identified by mass spectrometry. The second method 
(right) involves substrate labeling followed by tryptic digest. Labeled peptides are captured on beads, then 
released after washing and analyzed by mass spectrometry. 
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Figure 3.3  Substrate labeling followed by immunoprecipitation and mass spec analysis yields a 
candidate list of 607 putative PERK substrates. (A) Immortalized mouse embryonic fibroblasts 
expressing either PERK wild type or M886A were gently permeabilized, then incubated with thapsigargin 
and N6-furfuryl ATPγS for substrate labeling. Lysates were alkylated, assessed for labeling efficiency by 
western blot (left), then subjected to immunoprecipitation with an α-thioP antibody. Immunoprecipitated 
proteins were run on an SDS-PAGE gel and silver-stained (right). Bands were cut for mass spectrometric 
analysis. (B) Mass spectrometry identified 607 candidate substrates in PERK AS lysates that were not 
found in PERK WT. Candidates were sorted into GO categories that were enriched over reference set.  
B 
A 
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Figure 3.4  Independent confirmation of ATF6 and Ire1 as PERK substrates. (A) Cells expressing 
PERK WT or M886A were transfected with expression vectors carrying either HA-tagged Ire1 or FLAG-
tagged ATF6α. Cells were then labeled and alkylated as described in Fig 3.3. Labeling efficiency was 
assessed by western blot for total thio-phosphorylated protein. (B) Lysates were immunoprecipitated with 
anti-HA beads. Immunoprecipitates were assessed by western blot for Ire1 pull-down (left) and thio-
phosphorylated protein (right). (C) Lysates were immunoprecipitated with anti-FLAG beads. 
Immunoprecipitates were assessed by western blot for ATF6 pull-down (left) and thio-phosphorylated 
protein (right). 
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Figure 3.5  In vitro kinase assay for verification of ATF6 and phospho-site identification. FLAG-
tagged ATF6 was immunoprecipitated from 293T cells and incubated with recombinant PERK in the 
presence of ATPγS. Reactions were alkylated, run on an SDS-PAGE gel, and assessed for 
thiophosphorylated protein by western blot (left) or silver-stained for analysis by mass spectrometry (right). 
The two forms of FLAG-ATF6 are denoted by (*). 
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Figure 3.6 Substrate labeling followed by digestion and thiophosphopeptide capture. Cells were 
labeled as described in Fig 3.3. Thiophosphorylated proteins were assessed by western blot. For substrate 
identification, lysates were digested with trypsin and labeled peptides captured on iodoacetyl beads. Bound 
peptides were released with oxone treatment. Peptides were analyzed by tandem mass spectrometry.  
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Table 3.1 Thiophosphopeptide capture yields a candidate list of 35 putative PERK substrates with 
phospho-sites. ER-associated proteins are highlighted in orange, including PERK itself which is 
autophosphorylated.  
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Table 3.2 Independent identification of putative PERK substrates.  Substrate identification was 
performed via thioP immunoprecipitation or thiosphosphopeptide capture followed by mass spectrometry. 
One dataset was generated through immunoprecipitation and three biological replicates were analyzed for 
thiophosphopeptide capture. Overlap between and within datasets are represented, with thiophosphopeptide 
capture/MS denoted as “1” and immunoprecipitation/MS as “2”. 
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Figure 3.7  EEF1D is phosphorylated by PERK on serine 162 in vitro. (A) 293T cells expressing 
FLAG-tagged wild type or S162A EEF1D were lysed and subjected to immunoprecipitation with anti-
FLAG beads. Immunoprecipitated EEF1D was used as substrate for an in vitro kinase assay by incubating 
with recombinant PERK in a reaction supplemented with ATP. Reactions were run on an SDS-PAGE gel 
and analyzed for phosphorylated EEF1D by western blot with an anti-EEF1D pS162 antibody. PERK 
loading was verified by western blot with an antibody against total PERK; substrate loading was verified 
by Ponceau stain. 
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Figure 3.8  VAPB is phosphorylated by PERK in vitro. Recombinant PERK was incubated with 
recombinant VAPB in the presence or absence of ATPγS. Reactions were alkylated with PNBM, run on an 
SDS-PAGE gel, and assessed for thiophosphorylated protein by western blot.
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CHAPTER FOUR 
SUMMARY AND FUTURE DIRECTIONS 
 
     Protein kinases comprise a major class of enzymes that initiate and propagate 
signaling cascades critical for maintaining normal cellular function. It is therefore not 
surprising that disruption of protein kinase activity can have a significant impact on 
cellular and organismal fitness, as is frequently observed in diseases like cancer. Though 
many signaling events occur in the context of the cytoplasm, the endoplasmic reticulum 
also hosts an intricate signal transduction network. This network responds to changes in 
the environment that affect protein folding efficiency. Conditions in the tumor 
microenvironment can impinge upon protein folding, triggering ER stress signaling and 
initiating a cell adaptive response. This enables cancer cells to survive and thrive under 
the restricted conditions of the tumor microenvironment.  
     This body of work focuses on the ER kinase PERK, a key mediator of the UPR. 
PERK is instrumental in promoting an adaptive response through translational inhibition, 
and through transducing pro-survival signals to the nucleus. Numerous cancer-related 
functions have been ascribed to PERK, such as promotion of tumor cell survival, cell 
migration, increased metastatic potential, increased angiogenic potential, and 
chemotherapeutic resistance. Though the range of these attributes is broad, only three 
direct substrates of PERK have been identified to date. This has limited our 
understanding of the mechanistic details of PERK signaling under both homeostatic and 
oncogenic conditions.   
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     Herein, we have reported the identification and verification of an analog-sensitive 
allele of the ER kinase PERK (PERK M886A). Analog-sensitive kinases can be used for 
studying kinase function through small molecule-mediated inhibition as well as for 
mapping kinase-substrate interactions. We have utilized PERK M886A for both of these 
purposes, the implementation of which has been described in previous chapters, and the 
implications of which will be discussed in detail in the sections following.  
 
4.1 Perspectives on small molecule-mediated PERK inhibition  
     Given the multifaceted role of PERK signaling in tumorigenesis, there has been 
significant interest in developing small molecule PERK inhibitors. At the outset of this 
study, however, highly potent and specific inhibitors of PERK activity had not yet been 
reported. Therefore, one of our initial aims was to develop a system for PERK inhibition 
through chemical-genetic techniques, which would provide both relative ease in system 
design and generation, and high specificity in terms of inhibition. 
     The past two years have seen significant advances in PERK inhibitor development, 
which challenges the ultimate utility of PERK M886A for this purpose. In the first study, 
a screen of proprietary compounds for inhibitors of PERK catalytic activity toward eIF2α 
was performed (Axten et al, 2012). Lead optimization resulted in the identification of 
compounds with in vitro IC50s in the nanomolar range. Of these, 8 compounds exhibited 
activity in cells. Importantly, these compounds displayed at least 100-fold selectivity for 
PERK over the closely-related eIF2α kinases HRI and PKR. One of the most potent, 
selective compounds (GSK2606414) was further assessed for its in vivo efficacy in a 
human tumor xenograft model. At its highest dose, GSK2606414 inhibited pancreatic 
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tumor burden by 59%. A subsequent study of another compound identified in this screen 
(GSK2656157) demonstrated inhibitor-dependent restriction not only of tumor growth 
but also of blood vessel density and vascular perfusion (Atkins et al, 2013). PERK has 
been shown to upregulate VEGF, therefore, the inhibitory effect of this compound on 
angiogenesis is not unexpected, and is further evidence of PERK inhibition. In addition, 
an independent high-throughput screening of approximately 80,000 compounds resulted 
in the identification of two lead compounds that inhibit PERK catalytic function (Pytel et 
al, 2014). Unique to this study is the fact that both lead compounds are non-competitive 
PERK inhibitors.  The utility of these compounds in vivo remains to be established. 
     Despite promising results in the context of tumorigenesis, however, the highly specific 
small molecule inhibitors tested in vivo have had deleterious effects on pancreatic 
function. Though this certainly does not preclude the use of PERK inhibitors in treating 
neoplastic disease, it does highlight the fact that extreme caution should be used when 
considering treatment options. It may be possible to titrate the drug to a level of PERK 
inhibition that would restrict tumor burden while retaining enough activity to support 
pancreatic homeostasis. Transient inhibition may also lessen toxic effects on the 
pancreas. In addition, experimental evidence supports an approach wherein pancreatic 
function could be preserved through insulin supplementation (Gao et al, 2012). 
Administering exogenous insulin relieved the demand for insulin synthesis and secretion, 
which resulted in partial rescue of beta cell death. Finally, PERK inhibition may present a 
viable option for those with compromised pancreatic function, e.g. patients suffering 
from pancreatic cancer. 
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     Since this is an on-target effect of PERK inhibition, these results call into question the 
overall legitimacy of inhibiting PERK as a therapeutic strategy. Alternatives to PERK 
inhibition that are currently being explored target eIF2α (Sidrauski et al, 2013), IRE1α 
(Mimura et al, 2012; Papandreou et al, 2011), GRP78/BiP (Cha et al, 2009; Luo et al, 
2010; Martin et al, 2013; Matsuo et al, 2009; Pyrko et al, 2007), proteasomal degradation, 
and ERAD, among others (Clarke et al, 2014; Hetz et al, 2013; Li et al, 2011). These may 
offer the advantage of reduced organ toxicity in the clinic. 
     In terms of using the analog-sensitive PERK allele for inhibition studies in cells, we 
have uncovered an off-target effect of pyrazolo[3,4-d]pyrimidine (PP) inhibitors that 
precludes its use for this purpose. Alternatives to PP1 inhibitors are available (Zhang et 
al, 2013a) and may have fewer off-target effects if used in our system, or the gatekeeper 
mutation at M886 can be altered to accommodate an electrophilic inhibitor (Garske et al, 
2011). With the advent of highly specific commercially available PERK inhibitors, 
however, the gatekeeper system is of limited value, as it requires additional genetic 
manipulation of the kinase whereas general PERK inhibitors can immediately be used in 
many cell types. This is not meant to imply that the work presented in Chapter 2 is 
without value. To the contrary, our report demonstrates that the analog-sensitive allele of 
PERK is functional, i.e. that PERK M886A targets endogenous substrate in the context of 
cells, and initiates canonical PERK signaling with ER stress. Moreover, we have shown 
that the gatekeeper mutant was robustly inhibited by 3MB-PP1, which implies that the 
ATP-binding pocket of M886A was optimally modified to accept bulky ATP analogs. 
Both of these findings are imperative for the success of the subsequent PERK substrate 
screen described in Chapter 3. 
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     With regard to the enhanced survival phenotype observed with PP1 treatment, this 
phenomenon may be of interest for future study in its own right. The effect of PP1 
inhibitors on cell survival is dramatic, and has not been fully characterized in our study. 
For instance, it is not clear whether the effect on cell survival is PERK-dependent or 
UPR-dependent, or whether PP1 inhibitors activate another, as-yet-unidentified protein or 
survival pathway that is important for the response to ER stress. Exploration of these and 
other questions may lead to the discovery of novel ER stress related pathways, or 
connections between proteins or pathways that have not yet been forged. 
 
4.2 Potential for direct crosstalk between UPR pathways  
     The coming years will undoubtedly see further clarification of PERK signaling 
mechanisms through identification of additional interactors and downstream targets. 
From a clinical standpoint, this should provide the opportunity for more selectively 
targeting the oncogenic potential of PERK, while preserving its vital functions in cellular 
homeostasis. Prior to this study, there has only been one unbiased screen for PERK 
substrates (Cullinan et al, 2003). While this screen successfully identified the antioxidant 
response factor Nrf2, the list of PERK substrates has remained conspicuously small.  
     With the chemical-genetic screen described here, we have identified close to 700 
putative PERK substrates. Though this number may seem challenging to prioritize, we 
have generated substrate lists via two independent methods, which allows concentration 
on list overlap. Alternatively, it may be prudent to focus mainly on the list of 35 
substrates in its entirety, as this list is small enough to be manageable, and has the added 
advantage of defining phospho-sites for immediate mutagenesis. 
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     Three of the four putative substrates we have thus far pursued have been verified as in 
vitro PERK substrates. Our interest is particularly piqued by the identification of two 
master UPR regulators: ATF6 and IRE1. Indeed, previous studies have suggested 
interplay between the UPR branches with PERK being the initiating signal, though direct 
interaction between the three UPR sensors has not yet been demonstrated. For instance, 
the induction of ATF6-regulated genes was compromised in the absence of PERK in 
MEFs as well as in a liver-specific PERK knockout model (Teske et al, 2011; Wu et al, 
2007). Moreover, Teske et al demonstrated that PERK was required for full activation of 
~74% of all ER stress-induced genes in PERK KO livers, strongly suggesting pathway 
overlap. Mechanistically, these studies proposed that PERK facilitates ATF6 activation 
through promoting ATF6 cleavage (Adachi et al, 2008; Teske et al, 2011), and that this 
occurs at least in part through an eIF2α/ATF4-dependent pathway. We have verified that 
ATF6 is directly phosphorylated by PERK in vitro. Though there has been no evidence 
for ER stress-related phosphorylation of ATF6 prior to our study, previous work has 
shown p38-mediated ATF6 phosphorylation in myocardial cells (Thuerauf et al, 1998). 
This interaction was direct, as demonstrated by in vitro kinase assay. In addition, the 
requirement for p38 and the upstream activator MKK6 was demonstrated using a 
GAL/ATF6 reporter. A subsequent study, however, suggested that IRE1 overexpression 
was sufficient to activate ATF6 but that p38 was not required (Wang et al, 2000). Thus 
the question of whether ATF6 is activated through a mechanism unrelated to its 
proteolytic cleavage is largely unresolved, leaving the idea of PERK-mediated 
phosphorylation a tantalizing possibility.  
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     In following up on our initial results, the site of ATF6 phosphorylation is next to be 
determined. Several large-scale analyses by mass spectrometry have detected N-terminal 
phosphorylation of human ATF6 at Ser16 (Zhou et al, 2013) and Thr296 (Hornbeck et al, 
2012), which are within the cytoplasmic region we would expect to be phosphorylated by 
PERK. Mutagenesis of these sites, in addition to those derived from the scaled-up version 
of the in vitro kinase reaction followed by mass spec (Chapter 3), will be the most logical 
place to begin. 
     Though less well-studied, there also appears to be crosstalk between PERK and IRE1, 
with PERK signaling being required for stabilization of the spliced, active form of XBP1 
(XBP1s) that lies downstream of IRE1 activation (Huang et al, 2010; Majumder et al, 
2012; Teske et al, 2011). This was dependent at least in part on phosphorylation of eIF2α 
(Majumder et al, 2012), however, this does not preclude an even more direct involvement 
of PERK in IRE1 activation. Though the in vitro kinase assays we performed were 
inconclusive for technical reasons, our preliminary results suggest that PERK does 
phosphorylate IRE1 in permeabilized cells. Since IRE1 is a kinase, we have used the 
kinase dead allele (IRE1 K599A) to rule out the possibility that we are instead detecting 
IRE1 autophosphorylation. This mutant would also be useful for asking whether an 
IRE1-independent (potentially PERK-dependent) phospho-shift can be detected by 
western blot following ER stress. Ultimately, a direct assay for PERK-dependent 
phosphorylation will be required; a clear result here will likely be achieved through use 
of truncated, recombinant IRE1 that is of a significantly different molecular weight than 
PERK.  
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     For both ATF6 and IRE1 it will be important to determine the function of PERK-
mediated phosphorylation. Phosphorylation can alter conformation of the protein itself 
and thus alter activity, or it can result in the association or dissociation of interacting 
proteins. In terms of UPR crosstalk, it would be reasonable to speculate that these 
phosphorylation events might play a role in the temporal regulation of the three branches. 
In response to ER stress, PERK signaling is the first pathway to be activated, followed 
closely by ATF6 and eventually by IRE1 (Rutkowski & Kaufman, 2004; Yoshida et al, 
2003). PERK activation inhibits protein synthesis, which serves an immediate adaptive 
function by limiting the influx of nascent proteins to the ER. The second stage of UPR 
activation involves transcriptional upregulation, which is initiated by ATF6 processing 
and translocation of its cytoplasmic domain to the nucleus where it induces the 
expression of ER chaperones. ATF4-regulated genes are also induced downstream of 
PERK. Finally, IRE1 activation culminates in the induction of ER chaperones, as well as 
the induction of EDEM (ER degradation-enhancing α-mannosidase-like protein) which 
is required for degradation of remaining unfolded proteins after refolding is first 
attempted by ATF6 targets (Yoshida et al, 2003). These transcripts must be translated, 
which then requires relief of translational inhibition by GADD34 through 
PERK/eIF2α/ATF4. The timing of this response is imperative for appropriate UPR 
signaling, with translational repression followed by transcriptional upregulation and 
reinitiation of protein synthesis, followed by increased chaperone activity and protein 
folding, and finally degradation of proteins that are still unfolded. The temporal 
separation of these responses is consistent with the idea that PERK-mediated 
phosphorylation could enable full activation of ATF6 and IRE1 signaling at the onset of 
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stress. Alternatively, phosphorylation could serve to inhibit ATF6 and/or IRE1, thus 
preventing premature activation of the other two branches, or as a negative feedback 
mechanism for eventual attenuation of UPR signaling. Consistent with this idea, IRE1 
hyper-phosphorylation is required for its de-oligomerization and ultimate deactivation 
once ER stress has been resolved (Rubio et al, 2011). 
 
4.3 PERK in lipid metabolism  
     The endoplasmic reticulum is not only a major site of protein synthesis, but also a 
compartment essential for phospholipid synthesis. The ER itself can account for greater 
than 60% of phospholipid mass; its function is dependent upon appropriate phospholipid 
regulation and its composition, in a state of constant flux (Lagace & Ridgway, 2013). The 
major cell membrane phospholipid phosphatidylcholine (PtdCho) is synthesized in the 
ER, and is essential for ER expansion during stress. The Brewer lab elucidated a link 
between UPR signaling and phospholipid biosynthesis in work demonstrating that NIH-
3T3 cells overexpressing spliced XBP1 exhibited increased phospholipid levels, ER 
expansion, and activation of the PtdCho biosynthetic pathway (Sriburi et al, 2004). 
Moreover, ATF6 has also been implicated in regulating ER abundance. Subsequent 
studies showed that forced expression of ATF6α triggered ER expansion in multiple cell 
types, and that this expansion was independent of XBP1 expression (Bommiasamy et al, 
2009). 
     Though PERK has not yet been implicated specifically in ER expansion, studies have 
shown that PERK is required for sustained induction of the lipogenic enzymes FAS, 
ACL, and SCD1, and for activation of the transcription factor SREBP1, which targets 
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lipid metabolic genes (Bobrovnikova-Marjon et al, 2008). Interestingly, recent work has 
also demonstrated PERK involvement in phospholipid signaling. This study showed that 
PERK possesses lipid kinase activity toward the lipid precursor diacylglycerol (DAG), 
generating phosphatidic acid both in vitro and in vivo (Bobrovnikova-Marjon et al, 2012). 
PERK-dependent phosphatidic acid production, in turn, promotes mitogenic signaling 
through Akt activation, highlighting an important connection between PERK and 
metabolic pathways. 
     In our study, the transcription factor SREBP-2 was identified as a putative PERK 
substrate via thioP immunoprecipitation/MS. Sterol regulatory element binding proteins 
(SREBPs) are transcription factor precursors embedded in the ER membrane; SREBP-2 
is the main transcription factor responsible for regulating cholesterol biosynthesis, and as 
such, plays a major role in cell membrane biology. SREBP-2 is activated by agents that 
induce ER stress, and is proteolytically processed by the same proteases as is ATF6 
(S1P/S2P) (Colgan et al, 2007). The exact mechanism by which SREBP-2 is activated, 
however, has not yet been elucidated. It therefore remains possible that SREBP cleavage 
and activation could be facilitated by a phosphorylation event, e.g. phosphorylation 
mediated by PERK. Indeed, SREBP-1c and -2 were shown to be phosphorylated by 
AMPK, which in the case of SREBP-1c led to attenuation of the proteolytic processing 
required for activation (Li et al, 2011). Additional in vitro experiments should determine 
whether SREBP2 is a direct PERK target, and should successfully identify the phospho-
site involved. It will then be interesting to determine whether phosphorylation of this site 
is activational, which would be in keeping with the idea that ER stress activates SREBP 
pathways, or whether its phosphorylation inhibits SREBP function, which would be 
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consistent with conflicting reports suggesting an antagonistic relationship between PERK 
and SREBP (Harding et al, 2005). 
     Another putative PERK substrate identified in our screen, vesicle-associated 
membrane protein-associated protein B/C (VAPB/ALS8), falls under the category of 
lipid metabolism and phospholipid regulation. VAPB is particularly interesting for its 
characterized role in maintaining ER/Golgi structure and functional integrity through 
interaction with lipid-transfer/binding proteins (Amarilio et al, 2005; Peretti et al, 2008). 
Amarilio et al found that VAPB binds Nir family members through their conserved 
FFAT motif, and that VAPB-Nir overexpression differentially affected ER structure. The 
subsequent study from Peretti et al found that RNAi-mediated knockdown of endogenous 
VAPB disrupted Golgi architecture, altered the lipid composition of the Golgi membrane, 
impaired recruitment of Nir2, OSBP, and CERT, and disrupted Golgi-mediated 
trafficking.  
     VAPB is one of 35 proteins identified via thiophosphopeptide capture/MS in our 
study, with phosphorylation detected on Thr148. VAPB is an integral membrane protein, 
with a cytoplasmic region spanning residues 1-222; Thr148 therefore lies within the 
region we expect to be phosphorylated by PERK. The domains of VAPB have been 
previously described: the N-terminal MSP domain contains a conserved sequence that 
binds the FFAT motif, which is followed by a coiled-coil domain (CCD) and finally the 
transmembrane domain (TMD) responsible for VAP dimerization (Amarilio et al, 2005; 
Lev et al, 2008; Nishimura et al, 1999). Thr148 lies between the MSP and CCD, which is 
not immediately suggestive of a role in either FFAT binding or dimerization, however, 
phosphorylated residues in close proximity to Thr148 have been detected via large-scale 
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mass spectrometric analyses (Hornbeck et al, 2012). We have thus far confirmed VAPB 
as a PERK substrate by in vitro kinase assay; further experiments involving Thr148 
mutagenesis will be needed to both verify this site and to explore its function in vivo. 
     Given previous work, we speculate that the interaction between PERK and VAPB 
could regulate ER expansion and/or ER-Golgi trafficking. In line with this idea, our 
screen also identified several OSBP-like proteins as putative PERK substrates. The 
oxysterol-binding protein (OSBP) family is a conserved group of lipid binding/transfer 
proteins that regulate lipid flux, organelle lipid composition, and cell signaling (Olkkonen 
& Li, 2013). OSBP has also been shown to interact with VAPB through its FFAT motif 
in regulation of Golgi structure and function (Peretti et al, 2008), which may place 
PERK, VAPB, and OSBP in the same pathway. 
     Interestingly, recent studies have also implicated VAPB in the promotion of tumor 
growth via interaction with Akt (Rao et al, 2012). VAPB was overexpressed in patient 
breast cancer samples, and levels were negatively correlated with recurrence-free 
survival. Mechanistically, this study demonstrated that VAPB promotes cell proliferation 
as well as tumor spheroid growth through modulating Akt activity. In light of these 
results, it is possible that UPR activation in tumor cells promotes signaling through a 
novel PERK-VAPB-Akt pathway, which in turn promotes transformation and 
tumorigenesis. This hypothesis is consistent with previous reports demonstrating PERK-
dependent mitogenic signaling through Akt (Bobrovnikova-Marjon et al, 2012; 
Hamanaka et al, 2009). 
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4.4 PERK and translational regulation 
     The most well characterized role for PERK in the adaptive response to ER stress is 
arguably its influence on translation, i.e. its phosphorylation of eIF2α that inhibits 
translational initiation. This limits the influx of nascent proteins during ER overload. For 
this reason, it was of particular interest that our screen identified the translational 
elongation factor eEF1D as a putative PERK substrate. Furthermore, though not 
specifically reported in the preceding chapter, additional initiation and elongation factors 
were also identified in our immunoprecipitation/MS-based screen including eIF3 and 
eEF1A. This suggests the intriguing possibility that not only is translational initiation 
inhibited with ER stress, but that translational elongation may also be restricted through 
PERK activation.  
     Translational regulation enables rapid changes in the proteome, making this an 
effective way for cells to respond to stress. With ER stress, phosphorylation of the α 
subunit of eIF2 inhibits eIF2B, thus inhibiting the ability of the 43S preinitiation complex 
to recognize the start codon (Donnelly et al, 2013). Inhibition at the level of initiation is 
not the only stage at which translation can be repressed, however. Studies of the 
translational repression that occurs when cells undergo mitosis have provided additional 
insight into this phenomenon (Sivan et al, 2011; Sivan et al, 2007). During mammalian 
mitosis, translational repression at the level of elongation was evidenced by stalled 
polysomes as opposed to ribosomal runoff/polysome disassembly (Sivan et al, 2007). 
Mechanistically, this was thought to occur through eEF1D phosphorylation on Ser133, 
which reduces its interaction with eEF1A and thus results in fewer eEF1A-tRNA 
complexes that are able to deliver charged aa-tRNA to elongating ribosomes (Sivan et al, 
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2011). In the context of oxidative stress, translation is repressed at both the initiation 
stage via Gcn2-mediated eIF2α phosphorylation, and at the elongation stage in yeast 
(Shenton et al, 2006).  
     We therefore speculate that PERK phosphorylates not only eIF2α but also additional 
translation factors, such that the translational inhibition observed during ER stress is 
mediated through concomitant repression of both initiation and elongation. eIF3b/c were 
identified as putative PERK substrates, and are components of a multi-subunit complex 
that associates with the 40S ribosome and facilitates formation of the preinitiation 
complex. Multiple phosphorylation events have been detected on mammalian eIF3, 
however, none appear to have been characterized beyond their identification in large-
scale analyses (Hornbeck et al, 2012). A study in yeast has revealed phosphorylation of 
several components of the eIF3 complex, however (Farley et al, 2011). Interestingly, Prt1 
and Nip1, the yeast homologs of eIF3b and eIF3c, were phosphorylated and phospho-
sites assigned. Assuming conservation, these sites will be suitable for initial mutagenesis 
studies.  
     With respect to elongation factors, eEF1A and eEF1D were detected via different 
substrate identification methods in our set of screens. For eEF1D, the phospho-site 
detected was on Ser162, which was previously identified as a casein kinase II-mediated 
modification (Gyenis et al, 2011; Palen et al, 1994; Sheu & Traugh, 1997; Sheu & 
Traugh, 1999). The function of this modification and the conditions under which it is 
regulated have not yet been determined. Since eEF1A and eEF1D function in a single 
complex that facilitates the delivery of tRNA to ribosomes, it is possible that this 
interaction is disrupted via PERK-mediated phosphorylation of one or both components, 
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thus inhibiting translational elongation. Assays for interrogating the process of 
translational elongation have previously been described; these should guide initial 
experiments addressing whether translational repression occurs at the level of elongation 
during ER stress, whether PERK plays a role in said repression, and whether PERK-
mediated phosphorylation events are responsible for dissociation of elongation 
complexes or whether other inhibitory mechanisms come into play. 
 
4.5 Challenges and future outlook 
     In summary, PERK is involved in multiple stages of tumor initiation, progression, and 
metastasis, aspects of which are just beginning to become clear. Given the breadth of 
both cancer-related as well as homeostatic PERK functions, the near future will 
undoubtedly see heightened interest in and deeper understanding of the underlying 
molecular details of such functions. This thesis presents a characterized analog-sensitive 
PERK allele as a tool for studying PERK-mediated pathways, as well as a set of putative 
PERK substrates derived from two independent, optimized screens. These studies will 
provide a foundation from which to explore the mechanistic details of PERK signaling. 
     Not only have putative substrates been identified, but several novel connections have 
also been suggested between PERK and proteins involved in other UPR branches, in lipid 
metabolism and maintenance of ER-Golgi structure and function, and in translational 
regulation. Based on what we know about PERK function, additional expected categories 
of enrichment included metabolism, transmembrane and vesicle-mediated transport, and 
processes related to cell migration. Our screen also identified a large number of proteins 
that are not localized to the endoplasmic reticulum or involved in expected PERK-related 
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processes. This could indicate that PERK is in fact active in compartments other than the 
ER, an exciting idea that has been neither suggested nor refuted by the literature. Given 
that the ER has multiple contact points with both the nucleus and mitochondria, this is 
certainly not out of the question. On the other hand, the fact that non-ER-related proteins 
were identified as PERK substrates by our method could instead indicate that PERK was 
not maintained in its native compartment during cell permeabilization and subsequent 
manipulation. Though unlikely, it remains possible that even the low concentration of 
digitonin used to gently permeabilize cells resulted in disruption of intracellular 
compartments, and that PERK localization was compromised. If this is a concern in the 
future, PERK localization under the conditions used for the screen could be assessed by 
cell fractionation.  
     Another factor that might have resulted in spurious target identification is the 
possibility of bulky analog use by wild type kinases. Though our PP1 inhibitor results do 
suggest that bulky analogs have the potential for targeting proteins other than analog-
sensitive kinases, we have taken stringent measures to eliminate this factor from our 
dataset, i.e. we have subtracted the hits obtained using wild type PERK entirely from the 
final substrate list. Therefore, this list represents substrate phosphorylation that is solely 
dependent upon PERK M886A.  
     One of the obvious and immediate challenges in working with the list of 607 
substrates will be in culling it further to prioritize follow-up studies. One way of 
approaching this would be to conduct a biological replicate of the IP/MS screen. A repeat 
of this experiment could be done in precisely the same manner as described in Chapter 3, 
or it could include samples from unstressed cells as additional controls. Inclusion of these 
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controls was beyond the scope of this project, however, it would have allowed us to 
determine which were basal phosphorylation events, and which were specifically induced 
upon acute stress and thus intimately linked with UPR activation. Another approach to 
prioritizing the list would involve screening through the existing candidates via a more 
targeted, smaller scale method (e.g. peptide or protein array) or by using a combination of 
computational and genetic tools as has recently been described by the Krogan lab 
(Roguev et al, 2013).  
     Future directions for this work may also extend to the development of a screen using 
the analog-sensitive M886A allele to study PERK lipid kinase activity. Bobrovnikova-
Marjon and colleagues have demonstrated that PERK directly phosphorylates 
diacylglycerol (DAG) to generate phosphatidic acid (PA) in vitro and in vivo, and that PA 
formation is important for the activation of PERK-regulated mitogenic signaling 
(Bobrovnikova-Marjon et al, 2012). In light of this work, and the fact that numerous 
candidates from our screen fall under the lipid signaling and lipid metabolism categories, 
it seems likely that PERK directly phosphorylates proteins involved in these pathways as 
well as potentially phosphorylating lipids other than PA. Large-scale lipidomic studies 
have previously been hindered by analytical difficulties, however, with recent advances 
in lipid analysis by mass spectrometry, it might also be feasible to label lipids in a 
chemical-genetic manner to identify PERK-mediated modifications. 
     In conclusion, this thesis work provides us with a glimpse into the future study of 
PERK activity and function. Novel interactions and pathways downstream of PERK have 
been suggested herein, many of which will help clarify the mechanisms behind newly-
discovered PERK functions, such as the role of PERK in mediating the complex 
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processes of EMT (Feng et al, 2014), cell migration (Nagelkerke et al, 2013), metastasis 
(Mujcic et al, 2013), and ER-mitochondrial signaling (Verfaillie et al, 2012). Given that 
these data reflect an unbiased approach, we may also be led into entirely unexpected 
fields of study. We hope that such insights into the pro-survival nature of PERK signaling 
will ultimately contribute to the design and development of highly-specific, targeted 
therapeutic strategies in the treatment of cancer. 
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